TWI249518B - An agent for treating or preventing a rennal glomeralus disfunction - Google Patents
An agent for treating or preventing a rennal glomeralus disfunction Download PDFInfo
- Publication number
- TWI249518B TWI249518B TW092118405A TW92118405A TWI249518B TW I249518 B TWI249518 B TW I249518B TW 092118405 A TW092118405 A TW 092118405A TW 92118405 A TW92118405 A TW 92118405A TW I249518 B TWI249518 B TW I249518B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- compound
- glomerular
- substituted
- patent application
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 144
- -1 2,5-thiophendiyl Chemical group 0.000 claims abstract description 71
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 68
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 239000013543 active substance Substances 0.000 claims abstract description 30
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims abstract description 3
- 230000001434 glomerular Effects 0.000 claims description 69
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 61
- 230000004888 barrier function Effects 0.000 claims description 48
- 125000003277 amino group Chemical group 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 208000013901 Nephropathies and tubular disease Diseases 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 125000004414 alkyl thio group Chemical group 0.000 claims description 13
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
- 230000004064 dysfunction Effects 0.000 claims description 11
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 10
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 10
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 208000022461 Glomerular disease Diseases 0.000 claims description 6
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 5
- 125000002757 morpholinyl group Chemical group 0.000 claims description 5
- 125000006612 decyloxy group Chemical group 0.000 claims description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims 2
- 125000005577 anthracene group Chemical group 0.000 claims 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 229910052746 lanthanum Inorganic materials 0.000 claims 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical group [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 229910052712 strontium Inorganic materials 0.000 claims 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 59
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 42
- 239000002689 soil Substances 0.000 description 42
- 238000000034 method Methods 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 230000008569 process Effects 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 21
- 238000002844 melting Methods 0.000 description 20
- 230000008018 melting Effects 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 20
- 210000002700 urine Anatomy 0.000 description 20
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 230000029142 excretion Effects 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 125000003118 aryl group Chemical group 0.000 description 14
- 239000011159 matrix material Substances 0.000 description 14
- 201000008383 nephritis Diseases 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000010446 mirabilite Substances 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 230000002485 urinary effect Effects 0.000 description 8
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 7
- 125000004104 aryloxy group Chemical group 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 229960003624 creatine Drugs 0.000 description 6
- 239000006046 creatine Substances 0.000 description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- YOPAQWXLWNIFHM-UHFFFAOYSA-N 2-methylpropan-2-ol;hydrochloride Chemical compound Cl.CC(C)(C)O YOPAQWXLWNIFHM-UHFFFAOYSA-N 0.000 description 5
- 108050006400 Cyclin Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 5
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000921 elemental analysis Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 4
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 229920003114 HPC-L Polymers 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 201000001474 proteinuria Diseases 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 3
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 3
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000002570 interstitial cell Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 229910052707 ruthenium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical group O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- KBIAVTUACPKPFJ-UHFFFAOYSA-N 1-ethynyl-4-methoxybenzene Chemical group COC1=CC=C(C#C)C=C1 KBIAVTUACPKPFJ-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VHEKFTULOYIMSU-UHFFFAOYSA-N 4-ethenylbenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(C=C)C=C1 VHEKFTULOYIMSU-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- QIZPONOMFWAPRR-UHFFFAOYSA-N 4-phenoxybenzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1OC1=CC=CC=C1 QIZPONOMFWAPRR-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LUMNWCHHXDUKFI-UHFFFAOYSA-N 5-bicyclo[2.2.1]hept-2-enylmethanol Chemical compound C1C2C(CO)CC1C=C2 LUMNWCHHXDUKFI-UHFFFAOYSA-N 0.000 description 1
- WGYBIEOLAFYDEC-UHFFFAOYSA-N 5-bromothiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)S1 WGYBIEOLAFYDEC-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023435 Kidney small Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000000223 Solitary Kidney Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N cyclobenzothiazole Natural products C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 210000003904 glomerular cell Anatomy 0.000 description 1
- 231100000853 glomerular lesion Toxicity 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- ACULROWNTBIOLT-UHFFFAOYSA-N hexane ruthenium Chemical compound [Ru].CCCCCC ACULROWNTBIOLT-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920003113 low viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 125000004372 methylthioethyl group Chemical group [H]C([H])([H])SC([H])([H])C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- SCZVXVGZMZRGRU-UHFFFAOYSA-N n'-ethylethane-1,2-diamine Chemical group CCNCCN SCZVXVGZMZRGRU-UHFFFAOYSA-N 0.000 description 1
- DSWNRHCOGVRDOE-UHFFFAOYSA-N n,n-dimethylmethanimidamide Chemical compound CN(C)C=N DSWNRHCOGVRDOE-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical compound [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000009805 platelet accumulation Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 108010029690 procollagenase Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000012748 slip agent Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Description
1249518 玖、發明說明: 【發明所屬之技術領域】 技術領域 本發明爲有關具有優異蛋白尿抑制作用之腎小球障害防 治劑(尤其腎小球腎炎及糖尿病性腎症)防治劑,及具有優 異IV型膠原酶抑制作用及蛋白尿抑制作用(腎小球障害防 治劑)之新穎化合物。 【先前技術】 背景技術 腎小球乃由腎小球上皮細胞,環間膜(mesangium)細胞, 內皮細胞及保曼囊上皮細胞所構成。此腎小球將血液過濾 而生成原尿(含分子量1 0000以下之大致同血漿之成分)。 通常在過濾過程,血液中必須物質,尤其血淸蛋白被控制 不漏出尿中。 但在腎小球發生障害,則引起腎小球構成細胞之一之環 間膜細胞之增殖及其周邊基質之增生,而增加尿中蛋白之 排泄量。尿中蛋白排泄量增加,便知從腎小球障害乃至細 尿管障害腎功能下降。由此,藉抑制尿中蛋白排泄量而改 善隨伴於腎小球障害之種種病態。這種障害不僅爲原發性 者,如糖尿病等全身性疾病也能引起。但其發病進展機制 多仍未明,根本療法尙未確立。 目前之治療採行對症療法而有許多問題。例如,因腎炎 被認爲多由免疫學機制而起,故在腎炎患者使用免疫抑制 劑,但長期投與則發生腎毒性。也有使用類固醇劑,但有 1249518 對藥劑呈抵抗性之腎炎存在。最近獲知血管緊縮素轉換酶 抑制劑(降壓劑)對腎炎有效,但需求不降血壓而有作用之 藥劑。 如此腎小球障害之藥物治療尙呈試錯狀態。腎小球障害 之成因並不一樣,且臨床經過多色多樣而難預測,使治療 更加困難。 腎炎治療除上述以外,尙有特開平9 - 87 1 76記載之化合 物。 與本發明類似之化合物記載於W097 / 27 1 74,EP07 57984 Al,EP07 5703 7 A2,WO97/ 45402,W097/44315,W096/ 002 1 4,W09 5/ 3 5276,WO97/ 0 5 865。 鑑此,本發明者們就腎小球障害,尤其腎小球腎炎,糖 尿病性腎症硏究抑制發症之藥劑(抑制尿中蛋白排泄量之藥 劑)。 【發明内容】 發明之揭示 本發明者們用腎炎引起抗體來作成尿中蛋白漏出之腎小 球障害模式,以探索抑制其障害發症進展之化合物。結果 發現某種磺醯胺衍生物抑制尿中蛋白排泄量來抑制腎小球 障害(尤其腎小球腎炎,糖尿病性腎症)之發症進展,而可 當作其防治劑。 即本發明爲有關i)〜xxxix: i) 一種腎小球障害防治劑,內含有效成分爲如下式(I )化 合物,其光學活性體,或其製藥容許鹽或水合物: I2495i8 r4-r3-so〇-n R2
COY (I) 〔式中R1及R2各自爲H ,可有取代之低烷基,可有取代 之芳基,可有取代之芳烷基,可有取代之雜芳基,或可有 取代之雜芳烷基等; R3爲1,4-亞苯基或2, 5-噻吩二基; R4
R5
CSC—
R5
R5 或 (式中R爲H’ L基’可有取代之低院氧基’氯硫基,低院 硫基,環院基’鹵素’殘基,低院氧羰基,硝基,氰基, 低鹵烷基,芳氧基,可有取代之胺基,胍基,可有取代之 低院基,低稀基’低炔基’醯基,醯氧基,-(]〇腿18,-N(Rc)C0RD(式中RA,RB及Rc相同或相異,各爲Η,低烷基 或芳院基;RD爲低院基’芳基或芳院基),可有取代之非芳 -9· 1249518 族雜環基,或可有取代之雜芳基; R6爲可有取代之低烷基,環烷基’低烷氧基’鹵素,低 烷硫基,可有取代之胺基,羧基,低烷氧羰基’芳氧基, 苯基,可有取代之非芳族雜環基,或可有取代之雜芳基); Y 爲 NHOH 或 0H〕。 i i ) 一種腎小球障害防治劑,內含有效成分爲如下式(11 ) 化合物,其光學活性體,或其製藥容許鹽或水合物: R1
R7- r3-so2-n 入 COY (II) R2 〔式中R1,R2及R3同前 R7爲
Βθ~~〇·°Ξ〇~,
Re—或 r9一 (式中R8爲Η ’羥基,低烷氧基,氫硫基,低院硫基,環院 基’鹵素,殘基,低烷氧羰基’硝基,氰基,低_院基, 芳氧基,可有取代之胺基’胍基,可有取代之低院基,低 烯基,低炔基,烷醯基,醯氧基,或可有取代之雜芳基; R9爲可有取代之低烷基,環烷基,羧基,低烷氧羰基, 芳氧基,或苯基); -10- 1249518 Y 爲 NHOH 或 OH〕。 i i i ) 一種腎小球障害防治劑,內含有效成分爲如下式(j) 化合物’其光學活性體,或其製藥容許鹽或水合物: R1 R4 - R3-SO厂N 人 COY (I) R2 〔式中R1、R2、及R3同前; R4爲:
(式中R1()爲Η,可有取代之低烷氧基,低烷硫基,鹵素, 可有取代之胺基,可有取代之低烷基,或可有取代之非芳 族雜環基; R11爲可有取代之低烷基,低烷硫基,鹵素,可有取代之 胺基,苯基,可有取代之非芳族雜環基,或可有取代之雜 芳基); -11- 1249518 Y 爲 NHOH 或 0H〕。 1 v ) 種同小球障害防治劑,內含有效成分爲如下式(i i ) 化合物,其光擧活性體,或其製藥容許鹽或水合物: R1 Ϊ R7- R3 - SCVN^COY πη R2 C Rl' R2、及 R3 同前 R7爲:
9h C〜N— , 或 (式中R12爲H,齒素,硝基,可有取代之低烷基,低烷氧 基,或低烷硫基; R爲可有取代之低烷基或苯基); Y 舄 NH0H 或 〇H〕。 〜種腎小球障害防治劑,內含有效成分爲如下式(iii) 化合物,其光學活性體,或其製藥容許鹽或水合物: _ _ R1 r1〇-(III) R14
ί -ON 中R ,R1G及Υ同刖,R14爲Η或低烷基)。 -12- 1249518 v i ) —種腎小球障害防治劑,內含有效成分爲如下式(I V ) 化合物,其光學活性體,或其製藥容許鹽或水合物: R1
R
(IV) so2-n^coy R14 (式中R1,R12,R14及Y同前)。 v i i ) —種腎小球障害防治劑,內含有效成分爲如下式(V) 化合物,其光學活性體,或其製藥容許鹽或水合物:
(式中R1,R1G,R14及Y同前)。 v i i i ) —種腎小球障害防治劑,內含有效成分爲如下式(VI ) 化合物,其光學活性體,或其製藥容許鹽或水合物··
R
R1 S02—N 人 COY R14 (VI)
(式中R1,R12,R14及Y同前)。 i X ) —種腎小球障害防治劑,內含有效成分爲如下式(VI I ) 化合物,其光學活性體,或其製藥容許鹽或水合物:
-13- (VII) 1249518 (式中R1,R1G,R14及Y同前)。 X ) —種腎小球障害防治劑,內含有效成分爲如下式(VI I I ) 化合物,其光學活性體,或其製藥容許鹽或水合物:
(VIII) (式中R1,R12,R14及γ 同前)。 X i ) —種腎小球障害防治劑,內含有效成分爲如下式(I X ) 化合物,其光學活性體,或其製藥容.許鹽或水合物:
(IX) (式中R1,R1G,R14及γ同前)。 X i i ) —種腎小球障害防治劑,內含有效成分爲如下式(χ ) 化合物,其光學活性體,或其製藥容許鹽或水合物:
(式中R1,R12,R14及Υ同前)。 X 1 1 i ) —種腎小球障害防治劑,內含有效成分爲如下式(χ工) 化合物,其光學活性體,或其製藥容許鹽或水合物:
-14- 1249518 (式中R1,R1。,R14及Y同前)。
Xiv) —種腎小球障害防治劑,內含有效成分爲如下式(χιι) 化合物,其光學活性體,或其製藥容許鹽或水合物: R1
(式中R1,R12,R14及Υ同前)。 xv) —種腎小球障害防治劑,內含有效成分爲如下式(χι丨〗)修 化合物’其光學活性體,或其製藥容許鹽或水合物:
(ΧΠΙ) (式中R1,R1Q,R14及Y同前)。 xvi ) —種腎小球障害防治劑,內含有效成分爲如下式(χΐν) 化合物,其光學活性體,或其製藥容許鹽或水合物··
(XIV)
COY
,R (式中R1,R12 ’ R14及Y同前)。 x v i i ) —種腎小球障害防治劑,內含有效成分爲如下式(XV ) 化合物,其光學活性體,或其製藥容許鹽或水合物: -15- 1249518
s〇2 一 L COY (XV) (式中及γ同前)。 x v i i i ) —種腎小球障害防治劑,內含有效成分爲如下式 (XVI )化合物,其光學活性體,或其製藥容許鹽或水合物··
(式中R1,R13,RH及γ同前)。 X i X ) i )〜X v i i i )中任一項之腎小球障害防治劑,其中r i 爲Η’甲基.,異丙基,異丁基,可有取代之苄基,可有取代 之(吲哚-3 -基)甲基,或苯胺碳乙基。 XX) i )〜xvi i i )中任—項之腎小球障害防治劑,其中Ri爲 異丙基,苄基,或(吲哚· 3 -基)甲基。 X X i ) i )〜X X )中任一項之腎小球障害防治劑,其中r 2及R! 4 爲Η。 X X i i ) i )〜X X i )中任一項之腎小球障害防治劑,其中Υ胃 0H ° X X i i i ) i )〜XX i i )中任一項之腎小球障害防治劑,其中腎 小球障害爲腎小球腎炎。 X X i v ) i )〜x x i i )中任一項之腎小球fe害防治劑’其中腎小 球障害爲糖尿病性腎症。 -16- 1249518 XXV) —種如下式(XVII)化合物,其光學活性體,或其製藥 容許鹽,或其水合物:
R1 S〇2—N 人 COY R14 (XVII) (式中只1,!^,!^4及Y同前)。 xxvi ) —種如下式(XVI I I )化合物,其光學活性體,或其製 藥容許鹽,或其水合物:
R
S02—N R 又 14
COY (XVIII)
(式中R1,R1G,R14及Y同前)。 xxvii) —種如下式(XIX)化合物,其光學活性體,或其製 藥容許鹽,或其水合物:
R
S02
—N I R 14
COY (XIX)
(式中Ri’RM’R14及Y同前)。 xxviii) —種如下式(XX)化合物,其光學活性體,或其製 藥容許鹽,或其水合物:
R
S02一N R 又
COY (XX) -17- 14 1249518 (式中R1 xx i x )-容許鹽, ,R1G,R14 及 Y 同前)。 種如下式(XXI)化合物,其光學活性體,或其製藥 或其水合物:
(式中R1 XXX ) — 容許鹽, ,R1G,R14 及 Y 同前)。 重如下式(XXI I )化合物,其光學活性體,或其製藥 或其水合物:
(XXII) (式中R1 XXX i ) 一 藥容許鹽 ,R1G,R14 及 Y 同前)。 種如下式(XXI II)化合物,其光學活性體,或其製 ,或其水合物: n^JLsJ-s〇2i人 coy (ΧΧΠΠ) Rl4
(式中R1 XXX i i ) · 合物。 XXX i i i ) 中任一項 ,R1G,R14 及 Y 同前)。 一種醫藥組成物,內含xxv)〜xxxi)中任一項之化 一種受質金屬蛋白18.抑制劑,內含XXV)〜xxxi) 之化合物。 -18- 1249518 x x x i v ) —種I V型JP原18·抑制劑,內含x x v )〜x x x i )中任 一項之化合物。 X X X v )—種腎小球障害防治劑,內含X X v )〜X X X i )中任一 項之化合物。 XXX v i ) —種腎小球障害防治劑,內含有效成分爲如下式 (XXI V)化合物,其光學活性體,或其製藥容許鹽,或其水 合物··
R 15-so2-n^
COV (XXIV)
(式中各取代基之組合如下)=
I1249518 表1
化合物 NO. 1 γ R1 ,R2 1 ΝΗΟΗ (CH3)2CH· H 〇〇分 2 ΝΗΟΗ (ch3)2ch- Me 3 ΟΗ H 4 ΝΗΟΗ H 〇·〇分 5 ΟΗ (CH3)2CH- H QrQHOr 6 ΟΗ PhCH2- H 7 ΟΗ (CH3)2CH· H Me0HQJ^jL 8 ΟΗ 〇ά-,〇Η,- • · H MeSH〇J^]L 9 ΝΗΟΗ (CH3)2CH- H MeSHQJyL 10 ΟΗ (ch3)2ch- H bohq^til 11 ΟΗ (CH3)2CH H’ n-BuO-^^~— 12 ΟΗ PhCH2-- H 13 ΟΗ (CH3)2CH- 參1 K Me2N--^^—IgjL- 14 ΟΗ H Me2NHQjTjL 15 ΟΗ (CH3)2CH- H Ε12ΝΗ〇κζ3- 16 ΟΗ (ch3)2ch· H Et 17 ΟΗ. PhCH2- H Me ,_, ,-, Et 18 ΟΗ PhCH2- H B2N^JTjL
-20- 1249518
化合物 NO. Y R1 . R2 R15 19 OH 1 CHa- H Me2N-^y—isJ— 20 OH PhCH2- H h2nh0^4^ 21 OH PhCH2·· H 22 OH CHa- H 23 OH PhCH2- H o^oJvL 24 OH CH3· H 25 OH (ch3)2ch· H H2NHQJyL 26 OH (ch3)2ch·· H 27 OH (ch3)2ch- H Cn-〇j?- 28 OH H . H 29 • OH H . H [Ν_〇_ςΐ_ 30 OH H H 31 OH (CH3)2CH· H. MeS-O-^^O- 32 OH PhCH2- H 33 NHOH PhCH2- H 34 OH PhCH2- H 35 OH 0&l_- H 36 OH ΟΪ,ΟΗ,- H 37 OH 〇ά-(〇Η,- H
-21- 1249518 化合物 Nb. Y R1 R2 R15 38 ! OH (CH3)2CH· H 39 OH (CH3)iCH·- H 40 OH H 41 OH PhCH2·: H 42 NHOH (CH3)2CH- H 43 OH PhCH2- H 44 OH PhCH2- H 45 OH (CH3)2CH- H 46 OH (ch3)2ch· H 47 OH (ch3)2ch- H 4S OH . PhNHCO(CH2)2- H MeO-Ο-^Χ^- 49 OH PhCH2- H 50 OH PhCH2-. H 51 OH (CH3)2CH- · H 52 OH (CH3)2CHCH2- H 53 OH (CH3)2CH- H NC-O-^^ 54 OH (CH3)2CH- H 参 55 OH (ch3)2ch· H H2noc-<^-n.n^^^—
-22- 1249518 化合物 NO1. Y Rl 胪· R15 56 ΙΟΗ (CH3)2CH·. Η 57 OH ch3· Η 58 OH (CH3)2CH- · Η 59 OH MeS-CH2CH2- Η 60 OH 4-OH-Ph- Η 61 OH PhCH2- Η 一说办 62 OH PhCH2- Η 63 OH (CH3)2CH- Η MeO-^^-CEcJlgJi— 64 OH (ch3)2ch·· Η 65 NHOH (ch3)2ch- Η Me-^^C=C^SJ— 66 OH PhCH2- Η Cl -Ci c-^l s Jl— 67 OH PhCH2- Η MeO^^-CHC-Agjl— 68 OH Η Me-^^KCEcAgl— 69 OH Η MeO-^^CEcAgjL 70 NHOH Οώ-,οΗ,- Η Me-^^-CrcAgjL-- 71 NHOH (CH3)2CH· Η MeS-^y-C=cAsJL 72 NHOH 〇ώ-,〇Η,- Η CI-^^-CEcAgJL- 73 OH Η ci—<^^-c=cAsJL- •23- 1249518
化合物 N0. Υ Rl R2 R15 74 ,ΟΗ (CH3)2CH· H ci—^^-c=cAsi— 75 OH (ch3)2ch· H 76 OH O^L(ch,- H aH〇HGrc4^jl— 77 OH PhCH2- · H MeSH^^CHC^gJl— 78 OH Οώ-,οΗ,- H 79 OH (CH3)2CH· H MeS-^y-CzC-Xs3— 80 NHOH 必歐 H 81 OH Οώ-,ΟΗ,- H ho2hc-^^c^c-AsJL- 82 OH 〇ώ-,〇Η,- H 83 OH H 84 OH (CH3)2CH- H H〇V,^C-:cJQ- 85 OH PhClia-* • ·· H H0—nQ-cec-^]L- 86 OH 〇ά-,〇Η,- H 87 OH PhCH2- ft MeJlsiLc=cJ^sjL 88 OH 一 H Me"O-cic^〇- 89 NHOH 侧-. H MeOHQ-C=C-H〇- 90 OH . 必‘ H 91 OH ΟΛ,οη,- • H 〇2nhQhc-n-^^ 92 OH H 1249518 化合物 Ν〇· Y R1 R2 R15 93 OH I PhCH2- H 94 OH PhCH2-· H Mes 一 95 OH PhCH2- H 96 OH (CH3)2CH- H Me普: 97 OH (CH3)2CH- H p-^^-XjgL 98 OH (CH3)2CH· H 99 OH (CH3)2CH- *! H 100 OH (ch3)2ch· H 101 OH (ch3)2ch- H 102 OH (CH3)5CH· H 103 OH (ch3)2ch· .H MeH〇-^s 知 104 OH (ch3)2ch- H 分 105 OH PhCH2- H 分 106 OH (CH3)2CH· · H 分 107 OH (CH3)2CH. H 分 108 OH PhCH2- H 109 OH H 分 110 OH PhCH2- H βη〇ηΛν.νη〇Κ
-25- 1249518
化合物 NO·1 Y Rl •R2 R15 111 ?H H 112 OH (CH3)2CH- H 113 OH (CH3)2CHCH2· H 分 114 OH ch3· ; H 115 OH PhCH2- H 分 116 OH H H 分 117 OH CH3- H -6·^ 分 118 OH (CH3)2CH· · H 119 OH (CH3)2CH- H 120 OH (CH3)2CH- ·. H 121 OH (CH3)2CH- H
-26- 1249518 x x x v i i ) —種腎小球障害防治劑,內含有效成分爲如下式 (XXI V)化合物,其光學活性體,或其製藥容許鹽,或其水 合物:
R R1 15 - so2-n 人 R2
COY (XXIV) (式中各取代基之組合如下):
-27- I1249518 表2
化合物 No. Y R1 R2 R15 1 ΝΗΟΗ (CH3)2CH· H 2 ΝΗΟΗ (ch3)2ch- Me 3 ΟΗ CH,- H 4 ΝΗΟΗ ΟΔ-,οη,- H 〇-〇〇- 5 ΟΗ (CH3)2CH- H GOO- 6 ΟΗ PhCHi· H ooo- 7 ΟΗ (CH3)2CH. H 31 ΟΗ (ch3)2ch- H 32 ΟΗ PhCH2- H O-K^O- 33 . ΝΗΟΗ PhCH2- H 34 ΟΗ PhCHi- H 35 ΟΗ 〇^_- H -〇-〇-Nc<^ 36 ΟΗ Ο^,ΟΗ,- H 37 ΟΗ 0^_- H 38 ΟΗ (CH3)2CIL· H 39 ΟΗ (CH3)2CH- H 63 ΟΗ (CH3)2CH- H MeO-^^-CScAgjL- 64 ΟΗ (CH3)2CH. H Me-^^C=C^SJL
-28- 1249518 化合物 ) No. Y R1 . R2 R15 65 1 ΝΗΟΗ (CH3)2CH· H Me-^^-C=cAsJL 66 OH PhCHi- H 67 OH PhCH2· H Me〇-^^-C=C-X^]L 68 OH H Me 乂)-C 三 69 OH H MeO-^^-CHcAgjL- 70 NHOH H Me-^^CEcAgjL 71 NHOH (CH3)2CH· H MeS 乂) 72 NHOH H ci-三 c-isl- 88 OH 〇ώ-«〇Η,- H MeHQ"cEc"〇- 89 NHOH H MeOH^-CHCH^— 90 . OH H Br-Ο-ό-ίί-Ο- 91 OH H 92 OH 〇Λ,οη,_ H \ 93 OH PhCH2· H 94 OH PhCH2- H Μβ5Η〇Κ0-ί3Η〇- 1249518 x x x v i i i )如x x x v )〜x x x v i i )之防治劑,其中腎小球障害 爲腎小球腎炎。 X X X i X )如X X X v )〜(X X X v i i )之防治劑,其中腎小球障害爲 糖尿病性腎症。 上述化合物具有優異之腎小球防治作用,尤宜下列化合 物 化合物 No . 1、2、3、4、5、6、7、8、9、10、1 1、1 2、 13、 15、 16、 17、 18、 19、 20、 21、 23、 24、 26、 28、 29、 31、 32、 33、 34、 35、 39、 40、 41、 44、 48、 51、 52、 54、 55、 56、 57、 59、 61、 62、 73、 81、 82、 84、 86、 91、 92、 93、94、95、97、98、100、10卜 102、103、104、105、106、 107、 108、 109、 112、 113、 114、 115、 119、 120、 121° 更宜、化合物 No. 1、2、3、4、5、6、7、9、12、13、 15、 16、 17、 18、 19、 23、 29、 31、 32、 33、 34、 35、 39、 51、 54、 55、 56、 57、 59、 61、 62、 80、 82、 84、 86、 91、 92、93、94、95、96、97、101、108、112、113、115、119、 120 、 121 ° 尤宜、化合物 No. 1、2、4、7、9、12、15、16、17、18、 19、 23、 31、 33、 32、 34、 39、 54、 56、 57、 61、 62、 80、 84 、 86 、 91 、 92 、 95 、 97 、 101 、 108 、 121 ° 本文中,「腎小球障害」乃指由內因性或外因性要素引 起之腎小球之功能不全形態變化。 本文中「腎小球腎炎」乃指由遣傳性,外因性及自身免 -30- 1249518 疫異常以腎小球爲原發之腎功能障害。此亦包括不隨伴如 膜性腎症等炎症反應之腎症。 本文中,「糖尿病性腎症」乃指糖尿病發症後所認定之 所有之腎功能不全。 本文中,「低烷基」乃指直或分枝之1.6基。如甲基, 乙基,正丙基、異丙基、正丁基、異丁基、第二丁基、第 三丁基、正戊基、正己基等,宜Cr4烷基。 本文中,「環烷基」可爲如環丙基、環丁基、環戊基、 環己基、環庚基等。 本文中,「芳基」乃指單環或稠合環芳族烴環,如苯基, 1-萘基,2-萘基等。 本文中,「芳烷基」乃指於前述「低烷基」取代前述「芳 基」者,可在可能取代之任何位置鍵結。例如苄基,苯乙 基(2 -苯乙基),苯丙基(如3 -苯丙基),萘甲基(如1·萘甲 基,2-萘甲基),蒽甲基(如9 -蒽甲基)等。宜苄基。 本文中,「雜芳基」乃指環內有1個以上任意選自〇,S或 N之原子之5〜6員芳環,且可與前述「芳基」,「非芳族 雜環」或其他「雜芳基」稠合。這些可在可能取代之任何 位置鍵結。例如吡咯基(如1 -吡咯基),吲哚基(如3 -吲哚 基),咔唑基(如3 -咔唑基),咪唑(如4 -咪唑基),吡唑基(如 1 -吡唑基),苯駢咪唑基(如2 -苯駢咪唑基),吲唑基(如3 -吲哚基),吲畊基(如6 -吲畊基),吡啶基(如4 -吡啶基), 喹啉基(如5-喹啉基,異喹啉基(如3-異喹啉基),吖啶基(如 1249518 1 -吖啶基),菲基(如2 -菲基),嗒阱基(如3 -嗒畊基),嘧 啶基(如4 -嘧啶基),吡畊基(如2 -吡畊基),D幸啉基(如3 -哮啉基),呔畊基(如2 -呔畊基),喹唑啉基(如2 -睡唑啉基), 異喹唑啉基(如3 -異喹唑啉基),苯駢異喹唑啉基(如3 -苯 駢異喹唑啉基),噚嗤基(如2 -噚唑基),苯駢噚唑基(如2 -苯駢噚唑基),苯駢噚二唑基(如4 -苯駢噚二唑基),異噻唑 基(如3 -異噻唑基),苯駢異噻唑基(如2 -苯駢異噻唑基), 噻唑基(如2 -噻唑基),苯駢噻唑基(如2 -苯駢噻唑基),呋 喃基(如3 -呋喃基),苯駢呋喃基(如3 -苯駢呋喃基),噻吩 基(如2 -噻吩基),苯駢噻吩基(如2 -苯駢噻吩基),四唑基 等。宜吲哚基,吡唑基,吡啶基等。 本文中,「雜芳烷基」乃指於前述「低烷基」之任意位 置取代前述「雜芳基」者,可在可能取代之任何位置鍵結。 例如噻唑甲基(如4 -噻唑甲基),噻唑乙基(如5 _噻唑-2 -乙 基),吲哚甲基(如(B弓丨哚-3 -基)甲基),咪唑甲基(如4 -咪唑 甲基),苯駢噻唑甲基(如2 -苯駢噻唑甲基),苯駢吡唑甲基 (如1-苯駢吡唑甲基),苯駢三唑甲基(如4 -苯駢三唑甲基), 苯駢喹啉甲基(如2 -苯駢喹啉甲基),苯駢咪唑甲基(如2 -苯駢咪路唑甲基),吡啶甲基(如2 -吡啶甲基)等,尤宜(口弓丨 哚-3 -基)甲基。 本文中,「非芳族雜環基」乃指環內含1個以上任意選 自〇,S或N之原子之非芳族5〜7員環或這些2個以上 稠合者,如p比咯陡,派u定,哌哄,八氫睦啉,四氫呋喃, •32- 1249518 四氫吡喃,嗎啉,宜吡咯啶,嗎啉。 本文中「低烷氧基」乃指烷基部分爲前述「低烷基」之 烷氧基,如甲氧基,乙氧基,正丙氧基,異丙氧基,正丁 氧基,異丁氧基,第二丁氧基,第三丁氧基等,宜(^^烷 氧基。 「鹵素」乃指氟’氯,溴及碘,宜氟,氯及溴。 「低烷硫基」乃指烷基部分爲前述「低烷基」之烷硫基, 如甲硫基,乙硫基等。 「低烷氧羰基」乃指烷氧基部分爲前述「低烷氧基」之 φ 低烷氧羰基,如甲氧羰基,乙氧羰基,正戊氧羰基等。 「低鹵烷基」乃指以前述「鹵素」1〜5取代之前述「低 烷基」,如三氯甲基,三氯乙基,三氟甲基,三氟乙基等。 「芳氧基」乃指芳基部分爲前述「芳基」之「芳氧基」, 如苯氧基等。 「低烯基」乃指C2_6直或分枝烯基,如乙烯基,烯丙基, 丙烯基,丁烯基等。 「低炔基」乃指C2.8直或分枝炔基,如乙炔基,1-丙炔 ® 基,炔丙基,1-己炔基等。 「醯基」乃指於羰基鍵結前述「低烷基」或「環烷基」 之烷醯基,或於羰基鍵結前述「芳基」之芳醯基。例如乙 醯基,正丙醯基,異丙醯基,正丁醯基,第三丁醯基,環 丙醯基,環丁醯基,環戊醯基,環己醯基,苄醯基等,宜 乙醯基,苄醯基等。 -33- 1249518 「烷醯基」乃指於羰基鍵結前述「低烷基」或「環烷基」 之烷醯基,如乙醯基,正丙醯基,異丙醯基,正丁醯基, 第三丁醯基,環丙醯基,環丁醯基,環戊醯基,環己醯基, 宜乙醯基等。 「醯氧基」乃指於〇鍵結前述「醯基」之醯氧基。如乙 醯氧基,正丙醯氧基,異丙醯氧基,正丁醯氧基,第三丁 醯氧基,環丙醯氧基,環丁醯氧基,環戊醯氧基,環己醯 氧基,苄醯氧基,α-萘甲醯氧基,萘甲醯氧基等。 「可有取代之胺基」乃指由前述「低烷基」,「芳烷基」, 或「雜芳烷基」來1或2以上取代之胺基或非取代胺基。 如胺基,甲胺基,二甲胺基,乙基甲胺基,二乙胺基,苄 胺基等。 R1及R2之「可有取代之烷基」中取代基可爲羥基,烷氧 基(如甲氧基,乙氧基),氫硫基,烷硫基(如甲硫基),環 烷基(如環丙基,環丁基,環戊基,環己基),鹵素(如氟, 氯,溴,碘),羧基,低烷氧羰基(如甲氧羰基,乙氧羰基), 硝基,氰基,低鹵烷基(如三氟甲基),可有取代之胺基(如 甲胺基,二甲胺基,胺甲醯胺基),可有取代之胺甲醯基(如 苯胺甲醯基),胍基,苯基,苄氧基等。這些皆可在可能位 置取代1個以上。 R1及R2之「可有取代之烷基」爲甲基,乙基,正丙基, 異丙基,異丁基,苯胺甲醯乙基,甲硫乙基等。 R5,R6,R12及R13之「可有取代之烷基」中取代基可爲 -34· 1249518 可被保護之羥基(羥基,甲磺醯氧基,對甲苯磺醯氧基)’ 烷氧基(如甲氧基,乙氧基,正丙氧基,正丁氧基),疊氮 基’氫硫基,烷硫基(如甲硫基),環烷基(如環丙基,環丁 基,環戊基,環己基),鹵素(如氟,氯,溴,碘),羧基’ 低烷氧羰基(如甲氧羰基,乙氧羰基),硝基,氰基,低鹵 烷基(如三氟甲基),可有取代之胺基(如甲胺基,二甲胺基’ 胺甲醯胺基),胍基,苯基,苄氧基等。這些可在所有可能 之位置取代1個以上。適宜之取代基爲可被保護羥基,疊 氮基,鹵素,可有取代之胺基。 R5,R6,R12及R13之「可有取代之烷基」爲甲基,乙基, 正丙基,異丙基,正丁基,羥甲基,2 -羥乙基,2 -乙基疊 氮基,三氟甲基等。 R8 ’ R9,R12及R13之「可有取代之烷基」中取代基可爲 可被保護羥基(羥基,甲磺醯氧基,對甲苯磺醯氧基),烷 氧基(如甲氧基,乙氧基),疊氮基,氫硫基,烷硫基(如甲 硫基)’環院基(如環丙基,環丁基,環戊基,環己基),鹵 素(如氟,氯,溴,碘),羧基,低烷氧羰基(如甲氧羰基, 乙氧羰基),硝基,氰基,低鹵烷基(如三氟甲基),可被取 代胺基(如甲胺基,二甲胺基,胺甲醯胺基),胍基,苯基, 苄氧基等。這些可在所有可能之位置取代1個以上,適宜 之取代基爲可被保護羥基,疊氮基,鹵素,可被保護胺基。 「可有取代之烷氧基」中取代基可爲胺基(胺基,甲胺基, 一甲胺基,乙胺基’乙基甲胺基,二乙胺基)等。宜爲可有 -35- 1249518 取代之胺基。 「可有取代之烷氧基」可爲甲氧基,乙氧基,正丙氧基, 正丁氧基,3 -二甲胺丙氧基等。 本文中,「可有取代之芳基」,「可有取代之芳烷基」, 「可有取代之雜芳基」,及「可有取代之雜芳烷基」中芳 環上之取代基可爲如羥基,低烷氧基(如甲氧基,乙氧基), 氫硫基,低烷硫基(如甲硫基),環烷基(如環丙基,環丁基, 環戊基),鹵素(如氟,氯,溴,碘),羧基,低烷氧羰基(如 甲氧羰基,乙氧羰基),硝基,氰基,低鹵烷基(如三氟甲 基),芳氧基(如苯氧基),可有取代之胺基(如甲胺基,二 甲胺基,二乙胺基,亞苄胺基),胍基,低烷基(如甲基, 乙基,正丙基,異丙基,正丁基,異丁基,第二丁基,第 三丁基,正戊基,異戊基,新戊基,第三戊基),低烯基(如 乙烯基,丙烯基),炔基(如乙炔基,苯乙炔基),低烷醯基 (如甲醯基,乙醯基,丙醯基),醯氧基(如乙醯氧基),醯 胺基,低烷磺醯基(如甲磺醯基),苯基,苄基,疊氮基(如 苯疊氮基),可有取代之雜芳基(如3-吡啶基),可有取代之 志、基(如脲基,苯脲基)等。這些可在所有可能位置取代1個 以上。 「可有取代之非芳族雜環基」中取代基可爲低烷基(如甲 基,乙基,正丙基,異丙基)等。 「可有取代之非芳族雜環基」可爲1 -吡咯啶基,嗎啉基, 哌畊基,哌11定基’曙唑啶基等。 -36- 1249518 圖式之簡單說明 第1圖乃示由E-30抗體引起之尿中蛋白排泄量之經時 推移。 第2圖乃示藥物無處理群及檢體投與群之從實驗開始起 5日後每1腎小球之PCNA陽性細胞數。 第3圖乃示藥物無處理群及檢體投與群之從實驗開始起 5日後之血中尿素N濃度。 第4圖乃示藥物無處理群及檢體投與群之從實驗開始起 5日後之血中肌酸濃度。 籲 第5圖乃爲檢討對培養環間膜細胞增殖之影響’將3H -胸苷之吸取率以變化檢體濃度來經時地表示。 實施發明之最佳形態 本發明之腎小球障害防治劑之作用檢討如下。 (實驗動物) 採用5〜8週齢之Slc-Wistar系老鼠。 (腎炎引起抗體之作成) 以老鼠腎小球爲抗原作成小白鼠單株抗體。其中能引起 ® 腎炎之抗體篩選如下。 爲使抗體引起腎炎,抗原須在細胞表面。於是先將所得 之單株抗體靜脈注射在老鼠,以免疫組織化學調查是否聚 集在腎小球。 又就結合在腎小球之克隆調查其抗原之局在及分子量, 並以單次投與調查1週之尿中蛋白排泄量,以確定蛋白尿 -37- 1249518 之有無。 所得者爲E-30(日本腎臟學會誌,36卷,1994年,pl06)。 E-30已知依免疫組織化學認識環間膜細胞表面’又知單次’ 投與隨補體引起環間膜細胞障害,其經過如下。 對老鼠靜脈注射E- 30,則立即在腎小體環間膜細胞表面 結合抗體,次在3 0分以內補體被活性化。繼而引起環間膜 細胞之變性及壞死,終於腎小球基底膜從環間膜領域解離。 此現象乃稱環間膜融解。在此時期可看到血小板之集積, 多核白血球及巨噬細胞等炎症滲出細胞。環間膜融解在抗 體投與後1〜3日後變顯著,常見到環間膜領域膨大之狀態。 從第3〜5曰起開始以環間膜爲中心之細胞增生,一週時 呈明顯之環間膜增殖像。與環間膜細胞之分裂及增生一起 看到不規則之毛細血管之再生,腎小球毛細血管之再構築 起進展。經時增加之環間膜細胞及基質被整理,約1個月 大部分恢復近原來腎小球之形態。 如此單株抗體引起腎炎模式以單次投與呈現安定之發 症,故可用以把握作爲活體反應之腎小球病變之基本動態。 又在亞洲,I g A腎炎佔腎小球腎炎之半數。I g A腎炎以在 腎小球環間膜沈積I gA爲特徵,係以環間膜細胞本身爲標 的之免疫反應所產生之增殖性腎炎。故用單株抗體引起腎 炎模式,有助於IgA腎症之解明。 又作爲慢性腎炎模式,就倂用E-30及普拉黴素胺基核苷(puromycin ami no nucleoside)來引起之慢性腎炎模式(日本腎臟學會 -38- 1249518 誌,39卷,1997,p-220),及於摘除單腎之老鼠投與E-30 來引起之慢性腎炎模式(日本腎藏學會誌,39卷,1997,p-3 00 )進行評價,可評價能否預防或抑制腎小球硬化之進展。 同樣實驗可依1 )E-30代之以Thy - 1單株抗體或抗胸腺抗體 之方法,2 )用遺傳性腎病老鼠及小白鼠之方法,3 )用小白 鼠及老鼠自然發症糖尿病模式之方法,4)用小白鼠或老鼠 投與鏈脲菌素或尿囊素引起之糖尿病模式動物之方法來施 行。 (分析法) 於5〜8週齢老鼠靜脈注射E-30抗體20-〜500#g,宜50 〜200 // g來引起腎炎。將檢體化合物懸浮在3〜10%,宜4 〜6%阿拉伯膠溶液,在E-30投與之1〜5小時前,宜1.5 〜3小時前,口服0 . 1〜500mg,宜1〜200mg。以後每曰1 〜3次連續投與同量檢體化合物。檢體化合物之評價乃以蛋 白尿呈峰之第2日之尿中蛋白排泄量爲指標來施行。 對依此方法呈現活性之化合物,就5〜8日期間尿中蛋白 排泄量,體重變化,解剖時之腎小球之形態,環間膜細胞 增殖抑制率,腎功能予以解析。 尿中蛋白排泄量乃用不銹鋼籠採24小時尿來定量尿中蛋 白。又就實驗終了時之血液測定尿素氮(BUN )及肌酸作爲腎 功能之指標。至於尿細管之指標,測定尿中N -乙醯基-冷-葡萄糖胺酶(NAG)之排泄量。又對抗體投與後之細胞增殖之 影響則算定增殖細胞核抗原(proliferating cell nuclear -39- 1249518 antigen:PCNA)陽性細胞數來檢討。至於形態變化,以光學 及電子顯微鏡來觀察。 本發明之腎小球障害防治劑化合物(I )可依W097 / 27 1 74 之方法合成。 「本發明化合物」一詞也包括製藥容許鹽或其水合物。 與如鹼金屬(鋰,鈉,鉀等),鹼土金屬(鎂,鈣等),銨, 有機鹼及胺基酸之鹽,或與無機酸(鹽酸,氫溴酸,磷酸, 硫酸等),及有機酸(乙酸,檸檬酸,馬來酸,富馬酸,苯 磺酸,對甲苯磺酸等)之鹽。這些鹽可依常法形成。 本發明化合物以防治上述疾病爲目的投與人時,可以散 劑,顆粒,錠劑,膠囊,九劑,液劑等口服,或以注射劑, 栓劑,經皮吸收劑,吸入劑等來非口服。又可於本化合物 有效量混合適合其劑型之賦形劑,粘合劑,潤濕劑,崩散 劑,滑澤劑等醫藥用添加劑來作成醫藥製劑。若爲注射劑 時,與適當之載體一起滅菌處理作成製劑。 投與量乃視疾病之狀態,投與途徑,患者之年齢或體重 而異,成人口服時,一般爲0.1〜100,宜1〜20mg/kg/曰。 【實施方式】 次舉實施例及試驗例來詳述本發明,但不限於此。 實施例中用下列簡稱:
Me :甲基 tBu :第三丁基 DMSO · —*甲亞楓 p-TsOH :對甲苯磺酸 -40- 1249518 (化合物之調製) 實施例1 HC1
工N入COOlBu 直 XXV
XXVI 第2製程 第3製程
XXVII
<〇^°_^^s〇2"h^CNH〇H 第1製程 將D-戊胺酸第三丁J旨鹽酸鹽(XXV)4 · 72克(22 · 5mmol )溶 在二氯甲烷100ml,在冰冷下先後加N-甲基嗎啉6 . 19ml (2 . 5 X22.5 mmol)及 4-苯氧苯磺醯氯 6.37 克(1.05 〜22.5 mmol)。 在室溫攪拌5小時後,以乙酸乙酯稀釋。有機層依序以1N 鹽酸,飽和碳酸氫鈉水洗淨,以芒硝乾燥,減壓濃縮,在 矽膠柱層析(氯仿/甲醇=50/ 1 ),從乙酸乙酯/己烷再結 晶,得融點1 3 9 - 1 40 °C之目的物(XXVI )8.13克(產率89.1 % ) 0 -41- 1249518 IR(KBr, V max cm.i) 3302, 1731, 1698, 1584, 1489, 1439, 1369, 1342, 1299, 1253, 1161, 1136, 1094, 835 NMR(CDCl3, (5 ppni):0.85(d, J=6.9Hz,3H), 1.00(d, J=6.9Hz,3H), 1.28(s, 9H),2.05(m.lH),3.62(dd,J=4.2,9.6Hz,lH)l5.08(d,J=9.6Hz,lH),6.97. 7.05(m,2H),7.18-7.28(m.4H),7.40(m,lH),7.75-7.8l(m,2H) [o:】d-44.4±0.8(c=1.008 CHCla 24?C) 第2製程 化合物(XXVI ) 3 · 23克(9 · 41 mmo 1 )溶在二氯甲烷36ml,加 三氟乙酸36ml(5〇X9.41nimol),在室溫攪拌3小時。在室 $ 溫攪拌5小時後,減壓蒸除溶劑,從乙醚/己烷結晶,得 融點 1 3 7 - 1 38 °C 之目的物(XXVI I )2 · 62 克(產率 96 · 9% )。 IR(KBr, v max cm-i) 3154, 1728, 1688, 1583, 1488, 1251 NMR(CDCl3,d ppm):0.89(d,J=7.0Hz,3H),0.98(dlJ=6.8Hzr3H)l2.12(ra, lH),3.80(dd,J=4.6f9.6HzflH)l5.17(d,J=9.6Hz,lH)l6.95-7.08(m,4H).7.13-7.45(m.3H),7.7〇.7.85(m,2H) [or ]d-3.7±0.4(c=1.006 DMSO 24*C) 第3製程 · 化合物(XXVI I )〇·3克(〇.854mm ol)溶在二氯甲烷10ml, 在冰冷下先後加草醯氯〇 · 37ml ( 5 X 0 · 854mmol ),二甲基甲 醯1滴’在室溫攪拌1小時後,減壓濃縮,溶在四氫呋 喃10ml °另在冰冷下含羥胺鹽酸鹽474mg( 8 x 0.854mm〇1) 及碳酸氫鈉861mg(12x〇. 8 5 4mmol )之四氫呋喃10ml及水 6m 1混液中«拌5分,而在冰冷下加前述醯氯溶液,在室 -42- 1249518 溫攪拌1小時後,以乙酸乙酯萃取,以飽和碳酸氫鈉水洗 淨,以芒硝乾燥,減壓濃縮,在矽膠柱層析(氯仿/甲醇二 2 0/ 1 ),以己烷結晶,得化合物(1 ) 288mg(產率92 . 5% ), 物理常數如表3。 實施例2〜6 仿上合成化合物(2 )〜(6 ),結果如表3。 表3
参考例 No. 化合物 No. [a]D (DMSO) 融點 〇C) IR (v cm*1) (KBr) 不對稱 碳之組態 1 1 • 11.2 土 0.7 (25t:,c=0.705) •149-151 3628,1634,1584,1488,133 6,1253,1157 R 2 2 110-111 3323, 1678, 1328, 1150 R 3 3 82.87 3410,3276,1724,1582,148 8,1331,1152 (Nujol) R 4 4 115-118 3302,1667,1324,1153 (Nujol) R 5 5 241.243 1734, 1719, 1324, 1160 R 6 6 224-226 1750, 1324,1159 R 7 7 174-176 1735, 1503, 1343, 1163 R
-43- I2495l8 實施例 HC1 第1製程
H2N COOMe XXVIII
Br—^ >-S02-N COOMe S H XXIX 第1製程 第3製程
MeO-^^LsJLs〇2-N^COOMe
Me〇-^~^—LsJ^S02-N^C00H 第1製程 化合物(XXVI I I ) 7 5 5mg(4 · 5_ol )溶在二氯甲烷12ml,在 )水冷下加N -甲基嗎啉1.49ml(3x4.5mmol)及5 -溴噻吩- 2-磺醯氯1 · 24克(1 · 05 X 4 · 5mmol ),在室溫攪拌1 5小時後, 依序以2N鹽酸,5 %碳酸氫鈉水及水洗淨,以芒硝乾燥, 減壓濃縮,在矽膠柱層析(乙酸乙酯/正己烷=1 / 3 ),以 鲁 正己烷洗淨,得融點109 - 1 10°C之目的物(XXIX) 1 . 32克(產 率 82% ) 〇 [ct]D-34.5±0.7(c=1.012 CHCb 25eC) m IR(CHCl3, v max αη·ι)1737,1356,1164,1138. NMR(CDCl3,d ppm): 0.89(d,J=6.8Hz,3H), 1.00(d,J=6.8Hzf3H)f 2.00 (m.lH), 3.60(s,3H), 3.83(dd,J=5.2,10.0Hz,lH), 5.20(d,J=10.0Hz,lH), 7.04(d,J=4.lHzflH),7.32(dtJ=4.lH2,lH). -44- 1249518 第2製程 化合物(XXIX ) 500mg( 1 · 4mmol )溶在四氫呋喃12ml,加粉 末碳酸鉀3 87mg( 2 X 1 · 4_〇 1 ),4-甲氧苯基硼酸3 1 9mg( 1 · 5 Xl.4mmol),肆三苯膦鈀 81mg(0.05Xl.4mmol),在氬大氣 7 5 °C攪拌48小時後,以乙酸乙酯稀釋,依序以1N鹽酸’ 5 %碳酸氫鈉水及水洗淨,以芒硝乾燥,減壓濃縮’在矽膠 柱層析(正己垸/乙酸乙酯=3 / 1 ),以正己院結晶’得融 點 1 22 - 1 2 3 °C 之目的物(XXX) 447mg (產率 83% )。 元素分析 C17H21NO5S2 計算値 C;53.25 Η;5·52 N;3.65 S;16.72 實験値(:;53.26 仏5.50 1^;3.69 5;16.63-[a】D-21.7±0.6(c=1.000 DMSO 25eC) IR(KBr,v max cm-i)1735,1605,15Ό5,1350,1167,1136. NMR(CDC13,cJ ppm):0.90(d,J=7.0Hz,3H),1.00(d,J=6.6Hz,3H),2.10(m, 1H),3.54(8,3H)f3.85(s,3H),3.87(dd,J=5.0,10.2Hz, lH)t5.20(d,J=10.2Hz,lH),6.94 (d,J=9.0Hz.,2H),7.52(d,J=9.0Hz,2H),7.11(d,J=4.0Hz,lH),7.49(d,J=4.0Hz,lH) 第3製程 (义乂乂)39〇1112(1.01111111〇1)溶在四氫呋喃81111及甲醇81111之 混液,加1N NaOH 5 . 1 m 1,攪拌加熱60°C 6小時後,減壓 蒸除有機溶劑,以乙酸乙酯稀釋,以檸檬酸水溶液來酸化, 以乙酸乙酯萃取,以食鹽水洗淨,以芒硝乾燥,減壓濃縮, 得373mg(產率100%)之化合物(7)。物理常數如表4。 實施例8〜3 0 仿上合成化合物(8 )〜(3 0 ),結果如表4。 -45- 1249518
表4
参考例丨 No. · 化合物 No. [a]D (DMSO) 融點rc) IR(v cm-OOEOBr) 不對稱 硪之組態 8 81· +23·6 土 0·6 (24*C,c=1.000) 226-230 3415,1735,1341,1159 R 9 9 182-187 3260,1670,1635, M30,1335, 1158 U 10 10 •40.5 土 1.6(22t:,c =0.504 MeOH) 157.5- 158.5 343 l(br),3280,1690,1606, 1352,1168 R 11 11 •38.5 土 1.6(22% c =0.502 MeOH) 140- 141.5 3423(br),3330,1728,1686, 1349,1167 R 12 12 -42.2 土 1·6 (23t:, c=0.505) 198-202 3422,3301,1749,1362,1152 R 13 13 -65.2 土 2.1 (23t:, c=0.505) 194-198 3433,3325,1748,1366,1157 R 14 14 +22.6 土 1.2 (27^, c=0.504) 3390,3303,1746,1609,1322, 1156 R 15 15 •24.1 土 1.3 (24X:, c=0.507) 156:158 3433,3330,1736,1699,1346,1162 R 16 16 •18.2 土 1.2 (27t:f c=0.506) 182-184 3297,1701,1606,1346,1162 R 17 17 168-170 3277,1719,1606,1346,1159 R 18 18 -1.2 土 0·9 (26X:, c=0.504) 128-131 3433,3277,1715,1606,1341,1158 R 19 19 •2.0 土 0.9 (26t:, c=0.505) 222-224 3310,1752,1609,1319,1159 R 20 20 216-219 3269,1710,1608,1323,1150 R 21 21 _ 180-186 3345,3306,1710,1607,1354,1154 R 22 22 •2.0 土 0.9 · (26*C, c=0.505) 219-221 3310,1752,1609,1319,1159 R 23 23 270-272 3280,1723,1607,1436,1335,1157 R 24 24 +3.0 士 0.9 (27^, c=0.501) 148-151 3493,3240,1714,1329,1162 R 25. 25 -18·4±1·2 (27t:, c=0.501)u 220-223 3288,1716,1607,1432,1320,1157 R 26 26 •13.4 士 1.1 (27X:, c=0.507) 207-212 3431,3279, Π09,1607,1343,1163 R 27 27 •22.2 土 1,2 (27X:, c=0.500) 199-200 3463,3270,1736,1608,1319,1156 R 28 28 210-212 3333,3276,1747,1610,1316,1151 R 29 29 214-217 3426,3357,1714,1608,1330, 1152 R 30 30 +15.6 士 1.1 (26t:, c=0.508) >230 decomp. 3417,3296, 1744, 1322, 1155 R -46- 1249518 實施例4 HC1Η〆 、(300ιΒιι 第1製程 ^COO'Bu 第2製程
XXXI 第3褽程 〇-
XXXII 〇2H Η
S一N-N=C Ο so2-n-coo«bu
XXXIII 第5製程.
MeS—《S〇2-N " ΟΟΟιΒιι Ν=Ν
XXXIV MeS^^_N:N
31
s〇2-[1 C00H
第1製程 化合物(XXV) 20. 94克(99.8mmol )溶在二氯甲烷200ml,在 冰冷下先後加N-甲基嗎啉22ml(2X99.8mmol)及對苯乙烯磺 醯氯20·27克(9 9.8mmol),在室溫攪拌15小時後,依序以2N-鹽酸,5 %碳酸氫鈉水及水,以芒硝乾燥,減壓濃縮,在矽膠 柱層析(乙酸乙酯/正己烷/氯仿=1 / 3/ 1 ),以正己烷洗 淨,得融點118-120 °C之目的物(XXX 1)28· 9 3g (產率85% )。 -47- 1249518 IR(KBr,v max cnri)3419,3283,1716,1348,1168. NMR(CDCl3,(y ppm):0.85(dfJ=6.9H7,3H),1.00(d(J=6.6Hz,3H),1.21(s, 9H),2.04(m,lH)r3.62(dd,J=9.8;4.5HzllH),5.09(d,J=9.8Hz,lH)>5.41(dd,J=0.5.10 • 9Hz,lH),5.84(dd,J=0.5· 17.6Hz,lH),6.72(dd,J=10.9,17.6Hz, 1H),7.49(cU=8.4Hz ,2H),7.79(d,J=8.4Hzf2H). 第2製程 化合物(XXXI ) 5 · 09克(1 5mmol )溶在二氯甲烷300ml,在· 78C通'入臭氧15分後,加甲基硫22ml(2〇X15mmol),以80 分昇至室溫,減壓濃縮,得6 · 03克醛體(XXXI I )。 IR(CHCb, v max cm-i)3322,1710,1351,1170. NMR(CDCl3,tf ppm):0.85(d,J=6.9Hz,3H),1.00(d,J=6.9Hz,3H),1.22(s, 9H),2.07(m,lH),3.69(dd,J=4.5,9.9Hz,lH),8.01(s,4H),10.08(s,lH). 第3製程 化合物(XXXII)6.02克(15mmol)溶在乙醇60ml及四氫呋 喃15ml之混液,加苯磺醯肼2.72克(1.05X15mmol),在 室溫攪拌2小時後,減壓濃縮,在矽膠柱層析(氯仿/乙 肇 酸乙酯=1/ 4),從乙酸乙酯再結晶,得融點1 6 3 - 1 64 °C之 目的物(XXXIII)4.44mg(從第2製程產率60%)。 元素分析 C22H29N3〇6S2 . 計算値 C;53.32 H;5.90 Ν;8·48 S;12.94 實験値 C;53.15 H;5.87 Ν;8·32 332.82 [a ]d-11.6± 1.0(c=0.509 DMSO ·23·5β〇 -48- 1249518 IR(KBr,v max cm])3430,3274,1711,1364,1343.1172. NMR(CDC13,(5 ppm):0.84(d^J=6.9Hz,3H)l0.99(d,J=6.6H2,3H)>1.19(s,9H), 2.00(m,lH),3.63(dd,J=4.5,9.9Hz,lH),5.16(d,J=9.9HzflH)t7.50- 7.68(m;5H),7.73(s,lH),7.78-?.84(m,2H),7.96-8.02(m,2H),8.16(brs,lH). 第4製程 將4·甲氫硫基苯胺Ο . 14ml ( 1 · 1 1 X l_o 1 )溶在50%乙醇 水,加濃鹽酸Ο . 3m 1,在內溫0〜5 °C攪拌,加亞硝酸鈉 78 . 4mg( 1 . 1 4 X lmmo 1 )之水lml溶液,在同溫攪拌1 5分。 另將化合物(XXXI I I ) 496mg( lmmo 1 )溶在乾吡啶5ml,在-25 φ °C攪拌而以8分鐘添加上述反應液。在-1 5°C〜室溫攪拌4 小時後,倒入水中,以乙酸乙酯萃取,依序以2N鹽酸,5 %碳酸氫鈉水及水洗淨,以芒硝乾燥,減壓濃縮,在矽膠 柱層析(氯仿/乙酸乙酯=1/ 9),得374mg(產率74% )化 合物(XXXIV)。 元素分析 C23H29N5〇4S2*0.3H2〇
計算値 C;54.27 Η;5·86 N;13.76 S;12.60 實験値 C;54.25 H;5.77 Ν;13·87 S;12.52 IR(KB.r, v max cm*〇3422,3310,17054345,1171. NMR(d6-DMSO,<5 ppm):0.83(d,J=6.9Hz,3H),0.86(d,J=7.2Hz,3H), 1.19(s,9H),2.00(m,lH),2.59(s,3H),3.54(dd,J=6.3r9.6Hz,lH),7.56(d,J=8.7Hz,2H) ,8.00(d,J=8.6Hzf2H),8.10(d,J=8.7H2,2H),8.33(d,J=9.6Hz,2H),8.34(dlJ=8.7Hz,2 H). -49- 1249518 第5製程 化合物(XXXIV) 3 5 3mg溶在二氯甲烷2 . 5ml及三氟乙酸 2 . 5πι 1之混液,在室溫攪拌3小時後,減壓濃縮,以乙醚 洗淨,得化合物(3 1 ) 3 08mg(產率98% )。物理常數如表5。 實施例3 2〜6 2 仿上合成化合物(3 2 )〜(6 2 )。其結果如表5〜6。
-50- 1249518
表5
参%洌 No·· 化合物 No. [a]D (DMSO). 融點 〇C) IR (v cm*1) (KBr) 不對稱 磺之組態 31 $1 194-195 1720,1343,1166 R 32 32 215-216 3700-2200, 3278, 1634, 1337, 1160 R 33 33 •2.8 土 0.9 (21.5t:f c=0.499) 194-195 3700-2200, 3278, 1634, 1337, 1160 R 34 34 188-190 2500-3600, 3445, 3325, 2104, 1727, 1687, 1347, 1168 R 35 35 +17.9 土 1·1 . (22^, c =0.508); 195-196 3700-2200(br),3411,3271, 1749, 1719, 1331, 1165 R 36 36 +16.0 土 0.6 (22^,0=1.004) 203-205 3394,1757, 1738, 1331,1163 R 37 37 +18.7 土 0.6 (25t:,c =1.005) 199-201 3468,1718, 1685, 1334, 1170 R 38 38 -9.9 士 1·0 (24^, c =0.503) 227-228 3422,3289,1696, 1348, 1171 R 39 39 •10.7 土 1.0 (24.5Τ:, c=0.504) 208-209 3700-2200(br),3260,1746, 1726, 1715, 1334, 1170 R 40 40 ·22·9±1·2 (23t:,c=0.51〇) 205-207 3413,1700,1314,1157 R 41 41 • 1/7 土 0.4 (24^,0=1.001) 205-207 3286,1730,1343,1165 R 42 42 197-200 3255,1650,1510,1333,1165 R 43 43 •3.9 土 0·4 (24X:,c=1.00D) 208-210 3452,3351,1715,1347,1167 R 44 44 189-191 3441,3296,1726,1686,1346, 1168 R 45 45 •33.4x1.5 (22ti-c =0.5009 MeOH) 188.5· 189.5 3432m3292,1714,1688,1347, 1165 R 46 46 -31.3 士 1·4 (22t:,c =0.508 MeOH). '175-177 3372,3334,3281,Π30,1712, 1348,1173 R 47: 47 -9.5 士 0.5 (24^:,0=1.003) 220-222 3446,3350, 1711,1347,1170 R 48 48 -16.1 土 1.1 (24^,0=1.000) 217-219 3358,3249,1726,1336,1163 R 49 49 +1·8±0·8 、 (24X:,c =0.504) 217-220 3333,1697,1732,1344,1170 S 50 . 50 217-219 3437,3332,172(2,1695,1345, 1169 S 51 51 •9.3 ±1.0 (25^,0=0.504) 204-206 3289,1696,1348,1175 R -51- 124951^
参考例1 No.' 化合物 No. [a]D (DMSO) 融點 oc) IR (v cm·1) (KBr) 不對稱 碳之組態 52 •32.9 土 1·5 (25T:fc =0.504) 152-154 3298,1739,1337,1163 R 53 53 •11.3 士 1.0 ·* (26t:,c =0.503) 3289,2231,1749,1345,1167 R 54 54 -9·5 土 1·0 (25t:,c =0.508) 192-193 3329,1728,1370,1172 R 5δ 55 •11·5±1·0 (25^^=0.500)- 3437,1686,1609,1340,1169 R 56 56 ·8.8±1.0 (25t:,c =0.500) 3262,1716,1653,1337,1170 R 57 57 +2.4 土 0.9 (25X:,c =0.501) 198-200 3268,1709,1346,1165 R 58 58 -12·7±1·1 (26*C, c =0.503) 3342,1719,1683,1315,1161 R 59 59 163-165 3214,1756,1724,1345,1164 R 60 60 -105.4 土 2.9 ' (27t:,c =0.501) 216-219 3334,3165,1740,1341,1162 R 61 61 ·3·8 土 0·9 (27t:,c =0.506) 184-187 3190,1744,1512,1313,1148 R 62 62 •5.0 土 0.9 (27^,0=0.503) 204-207 3285,1717,1652,1604,1425, 1342,1169 R
實施例6 3 HC1 第1製_程
H2N COOMe XXVIII
Br~S々s〇2f、C00Me
XXXV
•S〇9-N八C〇〇Me-.U_’程 63 ~jLs(
H
so2-n c〇〇h
H 第1製程 化合物(XXV) 7 5 5mg(4 . 5mmol )溶在二氯甲烷12ml,在冰 冷下先後加N -甲基嗎啉1.49ml(3X4.5mmol)及5-溴噻吩-2 -52- 1249518 磺醯氯1 · 24克(1 · 05 X 4 . 5mmo 1 ),在室溫攪拌1 5小時後’ 依序以2N鹽酸,5 %碳酸氫鈉水及水洗淨,以芒硝乾燥, 減壓濃縮,在矽膠柱層析(乙酸乙酯/正己烷=1 / 3 ),以 正己烷洗淨,得融點 109 - 1 1(TC目的物(XXXV) 1 . 32克(產 率 82% )。 [cr)D-34.5±0,7(c=1.0l2 CHCh 25°C) IR(CHCb, v max cm.i)1737,1356,1164,1138. NMR(CDCl3f(!) ppm): 0.89(d,J=6.8Hzf3H), 1.00(d,J=6.8Hz,3H), 2.00 (m.lH). 3.60(s,3H), 3.83(dd,J=5.2f10.0Hz(lH), 5.20(d,J=10.0Hz, 1H), 7.〇4(d,J=4.1Hz.lH),7.32((U=4.lHz,lH)· 第2製程 化合物(XXXV) 400mg( 1.12mmol)溶在二甲基甲醯胺5ml, 加4 -甲氧苯基乙炔222mg( 1 · 5 X 1 · 12mmol ),碘化銅(i ) 21mg(0.lX1.12mmol),在氬大氣下充分脫氣,次加氯化雙 (三苯膦)鈀(II)39mg(0.05xl.l2mmol),三乙胺 0.47ml(3 X 1 . 12mmol ),再於氬大氣下充分脫氣。在50°C,氬大氣下 加熱攪拌1夜後,以乙酸乙酯稀釋,依序以1N鹽酸,5% 碳酸氫鈉水及水洗淨,以芒硝乾燥,減壓濃縮,在矽膠柱 層析(正己烷/乙酸乙酯= 2/1),從乙酸乙酯/正己烷再 結晶,得融點131-132°C之目的物(XXXVI) 3 9 2mg(產率86 % )。 -53- 1249518 分析値 Cl9H21N〇5Sr0.2H2〇 計算値:C;55.51 H:5.25 Ν;3·41 S;15.60 實験値:C;55.80 Η;5·19 Ν;3·38 S;15.36 IR(KBr,ν max cm-i)3268,2203,1736,1604.1524,1348,1164.
NMR(CDCh#d ppm): 0.90((1,J=6.6Hz,3H), 1.00(d,J=7.0Hz,3H)f 2.00(mr 1H), 3.60(s,3H), 3.84(s,3H), 3.86(dd,J=5.(U〇.2Hz,lH), 5.21(d,J=10.2 Hz,lH).6.90(d,J=9.0Hz,2H),7.44(cl,J=9.0Hz,2H),7.12(d,J=4.0Hz.lH),7.44(d,J= 4.0Hz, 1H). 第3製程 化合物(XXXVI ) 407mg( 1 mmol )溶在四氫呋喃8ml及甲醇 8ml之混液,加IN NaOH 5 . lml,在60°C加熱攪拌6小時後, 減壓蒸除有機溶劑,以乙酸乙酯稀釋,以檸檬酸水來酸化, 以乙酸乙酯萃取,以食鹽水洗淨,以芒硝乾燥,減壓濃縮, 得化合物(63)373mg(產率100%)’物理常數如表7。 實施例64〜89 仿上合成化合物(64)〜(89) ’結果如表7〜8。 -54- 1249518 表7
参考洌 No· 化合物 No. [α]〇 (DMSO) 融點 (X) IR (v cm*1) (KBr) 不對稱. 硪之組態 63 63 194-195 1710,1604,1351,1216 R 64 64 -7.6 土 L〇 (25X:, c =0.503) 157-158 32(58, 2208, 1712, H30, UM, 1350, 1163, 1143 R 65 65 . 191-193 3290,3200,1670,1650 (Nujol) R 66 66 -3.5 土 0·4 (22*0,0=1.004) 153-154 3280, 3234, 1723, I486, 1423, 1345, 1228,. 1150, 1115, 1088, 1014, 830, 811,699 R 67 67 149-150 1695, 1334, 1184 R 68 68 180-182 1729, 1675, 1340, 1168 R 69 69 1605, 1523, 1340, 1151 R 70 70 201-202 3389, 3370, 2207, 1666, 1427, 1329, 1161 R 71 71 182-187 3260, 1670, 1635, 1335, 1160 R 72 72 3410, 2919, 2207, 1668, 1593, 1519, 1487, 1457, 1426 R 73 73 +19.8 土 0.6 (23t:, c =1.008) 227-229 1736, 1618, 1398, 1168 R 74 74 196-199 $ 3408, 3381, 3296, 3264, 2218, 1676, 1642, 1605, 1590, 1568, 1556,1516, 1457, 1425 R 、Ί5 75 -8·4 士 0.5 (22.5t:,c =1.005) 148-149 3329,2209,1703,1351,1167 R 76 76 +21.±0·6 (22.5^,0=1.012)- 171-173 3431,2205,1713,1353,1161 R 77 77 -6.6±0.5 (23t:, c =1.008) 208-209 3335,2202,1733,1351,1163 R 78 78 +20.1 土 0.6 (23t:,c =1.000) 3383,2202,1747,1323,1158 R 79 79 -15.6 土 0.6 (23^,0=1.001) 156-157 3260,2206,1709,1351,1162 R 80 80 . 3410,2207,1668,1593,1338, 1156 R 81 81 +10.3 土 1.0 (26*C, c =0.504) 218-219 3459,3384,2208,1720,1338, 1159 R 82 82 3412,3257,2202,1741,1604, 1338,1156 R 83 83 .+19.9 土 0.6 (24t:,c =1.007) 224-226 3406,3254,2^)3,1723,1341, 1161 R -55- 1249518
表8丨 参考例 No. 化争物 No. [a]D (DMSO) 融點 〇C) IR (v cm*1) (KBr) 不對稱’ 碩之組態 84 84 -8.9 士 0·5 (24t:, c =1.0.00) 204-207 3513,3227,2206, t712,1330, 1162 η 85 85 •4.6 土 0.5 (24t:,c =1.002) 215-217 3491,3263,2207,1720,1354, 1338,1160 R 86 86 +18.5 土 2.9 (26r,c =0.205). 214-218 3402,3308,2199,1736,1380, 1344,1162 R 87 87 -12.4土i.O (27'C,c =0.502) 158-160 3336,3166(br),2193,1735, 1698,1377,1164 R 88 88 +22.7 土 1.3 (25^, c =0.500) 227-229 3600-2400(br), 1736,1618, 1398,1168 R 89 8S • 196-199 3408,3296,2218,1676,1642, 1376,1355,1164 R -56- 1249518 實施例90
p-TsOH
H2N COOMe XXXVII
XXXVIII ώ〇 第2製悪 Η2Ν-^^ ^~S02"N^NC0QMe
XXXIX
第4製程
Br-'《〉~C - N~^》SOg^N^^COOMe
XL "COOMe 90 化合物(乂乂乂\^11)5.0克(12.8111111〇1)溶在二氯甲院5〇1111, 在冰冷下先後加N-甲基嗎啉4 . 2ml ( 3 X 12 · 8mmol )及對硝苯 磺醯氯3.78克(1.2X12· 8_〇1 ),攪拌一夜後,依序2N-鹽 酸,5 %碳酸氫鈉水及水洗淨,以芒硝乾燥,減壓濃縮,從 丙酮-正己烷再結晶,得融點1 72 - 1 74t之目的物 (XXXVIII )5.05 克(產率 97.8% )。 -57- 1249518 IR(KBr, y max cm*〇 3417, 3281, 1745, 1529, 1353, 1168. NMliide-DMSO,^ ppm):2.85(dd,J=9.8,14.6Hz,lH),3.08(dd,J=4.8,14.4Hz,lH), 3.56(s,3H), 4.02(ra, lH),6.84-7.30(m,5H),7.53(d,J=8.6Hz,2H),7.94(d,J=8.6Hz, 2H),8.83(brs,lH),10.37(s,lH).
[a]D+43.5± 1.6(c=0.508 DMSO 25eC) 第2製程 化合物(XXXVII I )5.0克溶在甲醇50ml及二甲基甲醯胺 10ml之混液,加10% Pd-C 1克,在室溫加氫1小時後, 濾除觸媒,減壓蒸除溶劑,從氯仿-乙醚再結晶,得融點 1 58 - 1 60°C 之目的物(XXXIX)3 . 43mg (產率 74 · 1 )。 IR(KBr,v max cm]) 3468, 3378· 3283, 1737, 1623, 1596, 1335, 1320, 1155. NMR(d6-DMSO,c5 ppm):2.85(dd,J=6.6,14.2Hz, 1H),3.00(dcl,J=8.2,14.2Hz, lH),3.30(s,3H),3.86(m,lH),5.93(s,2H),6.56(d,J=8.8,2H),6.90-7.10(m,3H),7.20-7.38(m,2H)· [ct】D+10.1±1.0(c=0.503 DMSO 25eC) 第3製程
化合物(XXXIX) 500mg( 1 . 3mmol )溶在二氯甲烷13ml,在 冰冷下加N-甲基嗎啉0 · 29ml ( 2 X 1 . 3mmo 1 )及對溴苄醯氯 371mg(1.3xi.3mmol),在室溫攪拌一夜後,加丁酮而依序 以2 N鹽酸,5 %碳酸氫鈉水及水洗淨,以芒硝乾燥,減壓 濃縮,從丙酮-正己烷再結晶,得融點2 1 5 - 2 1 8 °C之目的物 (XL) 720mg(產率 100% )。 -58- 1249518 IR(KBr, v max cm-ι) 3397, 3330,..1787, 1732, 1668, 1348,1337,1157. NMR(d6-DMSO,d ppra):2.90(dd,J=8.0,13.4Hz, lH),3.33(s,3H),3.06(dd,J=7.0, 14.8Hz,lH),3.97(dt,J=8,2,8,2Hz,lH),6.90-7.10(m,3H),7.24-7.32(m,2H),7.62(d, J=8.8Hz;2H),7.78(dfJ=8.4Hz,2H),7.86(d,J=8.4Hzf2H),7.93(d,J=8.8Hzt2H)l8.07 (d,J=8.8Hz,lH),8.39(d,J=8.8Hz,lH),10.59(s,lH).
[a]D-1.9±0.8(c=0.51 DMSO 25eC) 第4製程 化合物(XL) 807mg溶在二甲亞碾6ml,加IN KOH 2.9ml, 在室溫攪拌5小時後,加水而以2N鹽酸酸化。將析出結晶 水洗,得化合物( 90 ) 72Omg(產率78 . 7% ),物理常數如表9。 實施例9 1〜9 4 仿上合成化合物(9 1 )〜(9 4 ),結果如表9。 表 9
参考 例No. 化合 物No· [α]ο 融點 ro IR (v cm*〇 (KBr) 不對稱 磺之組態 90 90 +3.0±0·9 (25 eC , c =0.501) 215- 218 2800-3640, 3328, 1727, 1668, 1590, 1514, 1316, 1154 R 91 91 211- 213 1719, 1629, 1340, 1156 R 92 92 170· 175 1730, 1651, 1603, 1333, 1161 R 93 93 242· 244 2840.3600, 3346, 1752, 1726, 1656, 1610, 1324, 1160 R 94 94 •2 3 5二 235.5 25—50-3600, 3318, 1742, 1667, 1591, 1334, 1161 R 實施例95〜100 仿W0 97/ 27 1 74及上述方法,合成化合物(95)〜(100), 結果如表1 0。 -59- 1249518 表1 ο
参考 例 No·’ 化合 物No. [a】D 融點 CO IR ( v cm*1) (KBr) 不對稱 碩之組態 95 95 -29·4±1·4 , (25 eC , c =0.504) 166· 169 3437,1737,1376,1162 R 96 96 ·32·0± 1.4 (25 eC , c =0.503) 178· 179 3280,1702,1351,1165 R 97 97 -9·2± 1.0 (25 eC , c =0.503) 184· ;186 3282,1711,1354,1164 R 98 98 220- 223 3202,1748,1707,1376,115 6 R 99 99 ·9.9±1·0 (26 eC , c =0.504) 227- 230 3258,1725,1352,1159 R 100 100 -6.2±0.9 (24 eC , c =0.503) 203· 205 3437,3318,1709,1343,116 2 R
實施例1 Ο 1 XLI CHO 第1F3C-^~^-S=NNHS02-^^
XLII 第2製程
F3C
N
H2N y- S-N^C〇2Me XLIII N=N /r^v O ? 上一^—㈡〆^C02Me
XLIV 第·3製程’ f3c
N=N Λ:—λ 〇 ? -60- 101 1249518 第1製程 苯磺醯肼 1 · 722 克(lOmmol )及化合物(XL1 ) 1 . 43mg( 1 · 05 X lOmmol )溶在乙醇20ml及四氫呋喃2ml之混液,在室溫 攪拌3小時後,加水而以乙酸乙酯萃取,依序以2N鹽酸, 飽和碳酸氫鈉水及飽和食鹽水洗淨,以芒硝乾燥,減壓濃 縮,以己烷/乙酸乙酯結晶,得融點.1 42 - 1 44°C化合物 (XLII) 2.873g(產率 87.5% )。 IR(KBr, v max cm·») 3431, 3178, 1325, 1169, 1123. iH NMR (CDCb, δ ppm): 7.51-7.72 (m, 2H), 7.79 (s, 1H), 7.98-8.04 (m, 2H), 8.24 (br s, 1H). 元素分析(C14HuF3N2〇2S) 計算値·· C;51.22, Η;3·38, F;17.36, N;8.53, S;9.77 實験値:C;51.22, H;3.38, F;17.50, N;8.59, S;9.69 第2製程 化合物(XLIII) 572mg(2 mmol)溶在50%乙醇水20ml,加 濃鹽酸0· 84m卜在內溫0〜5°C攪拌,加亞硝酸鈉168mg ( 1 . 2 X 2mmol )與水3ml之溶液,在同溫攪拌20分。另化合物 (XLI I ) 6 5 7mg( 2mmol )溶在吡啶20ml,在- 25°C攪拌而加上述 反應液,在同溫1小時及室溫一夜之攪拌後,加水而以乙 酸乙酯萃取,依序以2N鹽酸,IN K0H水及飽和食鹽水洗淨, 以芒硝乾燥,減壓濃縮,在矽膠柱層析(氯仿/甲醇=50/ 1 ),從丙酮/己烷再結晶,得融點1 89 - 1 9 1 °C化合物 (XLIV) 63 7mg(產率 65.9% )。 -61- 1249518 IR(KBr,v max cm-i) 3282, 1735, 1350, 1328, 1165, 1127. m NMR (CDCb, δ ppm): 0.90 (d, J = 6.9 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H). 2.10 (m· 1H), 3·52 (s, 3H), 3.85 (dd, J = 4.8· 9.9 1H), 5.23 (d, J = 9.9 Ηζ· 1H), 7.79· 7.85 (m, 2H), 8.05-8.10 (m, 2H), 8.36-8.42 (m, 4H).
[a]D +· 3.9 ± 0.9 (c = 0.512, DMSO, 25 °C) , 元素分析(C2〇H2〇F3N5CUS) 計算値:C;49.69, Η;4·17: FU1.79, Ν;14.49· S;6.63 實験値:C;49.52, Η;4·17, F;.11.73, N;14.50, S;6.66 第3製程 化合物(XLIV)637mg(1.32mmol)溶在四氫呋喃8 ml及甲醇 8ml之混液,加IN Κ0Η水,在60°C攪拌一夜後,以2N鹽 酸酸化,以乙酸乙酯萃取,以飽和食鹽水洗淨,以芒硝乾 燥,減壓濃縮,以丙酮/己烷再結晶,得融點1 98 - 200°C 化合物(101)585mg (產率94.4%)。物理常數如表u。 實施例1 0 2〜1 2 1 仿上合成化合物(1 02 )〜(1 2 1 ),結果如表u。 1249518 表1 1
参考例 No. 化合物 No. [«]d 融點 IE(v cm-OOKBr) 不對稱 碳之組態 101 1 101 •4.2 土 0.9 (27X:, c=0.506) 203-208 3430,3290,1701,1610,134 4,1164 R 102 102 •9.1 士 1.0 (26t:( c=0.504) 224-226 3409,3329,1741,1610,159 0,1321,1163 R 103 103 •17.4 士 1.1 (27t:, c=0.506) 243-245 3335,1725,1348,1168 R 104 104 •7.7 土 1·0 (25X^=0.504)、 198-200 3270,1746,1326,1160 R 105 105 190-192 3339,3287,1719,1690,135 0,1167 (Nujol) R 106 106 •9.4 土 1.0 (25t:, c=0.500) 204-205 3317,3232,1762,1746,137 9,1161 (Nujol) R 107 107 •11.7 土 1·0 (25t:, c=0.505) 186-187 3302,3215,1762,1746,137 8,1161 (Nujol) R 108 108 •2.2 土 0.8 (25^, c=0.505) 187-189 3184,1739,1322,1146(Nu i〇l) R 109 109 +31.9 土 1.4 (25^, c=0.502) 125-126 3384,3268,1761,1712,133 2,1159 (Nujol) R 110 110 188-190 3182,1739,1322,1146 (Nujol) S 111 . 111 +33.7 土 1.5 (25^, c=0.504). 113-115 3286,1732,1683,1328,116 2 (Nujol) R 112 112 +7.8 土 1.0 (25X:, c=0.502) 179-181 3293,1713,1348,1145 (Nujol) S 113 113 •6,8 土 0.9 (25X:, c=0.504) 153-154 3179,1741,1709,1324,114 6 (Nujol) R 114 114 194· 195 3269,1709,1351,1152 (Nujol) R 115 115 191-192 3445,3288,1719,1670,159 5,1450,1350,1163 R 116 116 199-201 3316,2962,1715,1341,115 6 R 117 117 155-157 3272,1709,1350,1152 R 118 118 ·7·9±1·0 (26X:, c=0.504) 187-189 3316,1744,1309,1161 R 119 119 ·8·0 士 1.0 (26X:, c=0.503) 185-188 3284,1726,1370,1167, < R 120 120 ·9·1 土 1.0 (26t:, c=0.504) 194-196 3313,1739,1343,1164 R 121 121 -9.6 土 1.0 (2SC, c=0.502) 191-193 3263,1746,1329,1159 R 1249518 試驗例 試驗例1 令5週齡Slc-Wistar系雄鼠在室溫251,濕度40〜60 % ’明暗循環1 2小時之條件下自由攝取固形飼料(CA _ 1, 日本Clea製造)及自來水來預備飼養一週後,個別收容在 不銹鋼製代謝籠至7週齢(體重150〜180克)時供實驗。 將^3〇單株抗體(日本腎臟學會誌,36卷,1 994,01〇6)以 生理食鹽水稀釋而從尾靜脈投與lOOvg/O.4ml /老鼠。將化 合物(2)懸浮於5%阿拉伯膠溶液,在E-30投與之2小時前鲁 口服100mg,以後每日1次連續授與i〇〇mg,投與被驗化 合物之即後個別收容在不銹鋼製代謝籠而採集24小時尿。 所採集之尿在測定尿量後,在室溫以300 Or pm離心10分, 以上清供測定尿中蛋白排泄量。尿中蛋白乃用焦性沒食子 酸紅法(Micro TP-Test Wako,和光純藥製)來測定。實驗 開始2日後,將尿中蛋白排泄量對藥劑無處理群比較來算 定抑制率,結果如表1 1。化合物(1 )及化合物(3 )〜(1 2 1 )也 同樣實驗,結果如表1 2。又將實驗開始日至最後日之蛋白 ® 排泄量之推移與藥物無處理群一起列在第1圖。 -64- 1249518 表1 2 化合物No. 抑制率(%) 化合物No. 抑制率(%) 1 44.6 63 36.0 2 31.1 64 36.7 3 28.9 65 37.6 4 56.3 66 31.3 5 21.6 67 13.5 6 ' 27.1 69 · 25.5 7 48.0 70 25.8 8 14.4 71 30.4 9 30,¾ 72 21.1 10 2. 73 14 11 12.2 80 21.1 12 33.4 81 9 13 17.8 82 22.8 16 32 84 26.6 24 11.5 86 34 26 10.7 88 25.6 31 40.9 89 36.5 32 56.5 90 31.2 33 ,25.5 91 52.0 35 50.7 92 54.3 36 22.1 93 29.3 37 33.6 94 21.5 38 95 21 39 49.7 ^ 101 29 40 .1-〇·2 104 27 、 41 16 108 35 44 19 114 2.7
-65- 1249518 在實驗最末日(5日後),在戊基巴比妥麻醉下剖腹採血 後,摘出腎臟,以1 0 %福馬林液或美他卡倫溶液固定。以 福馬林液固定之試料作成石蠟切片後,予以過碘酸許& ^ 色而以光學顯微鏡觀察。 經美他卡倫溶液固定之試料則作成石鱲切片後,以對PCNA 之抗體(抗PCNA小白鼠I gG )予以免疫染色,測定在細胞周 期之S期之PCNA陽性腎小球構成細胞數,結果如第2圖。 在實驗最末日(5日後),採血而測定血中尿素N濃度及 血漿肌酸濃度。血中尿素N濃度係用肌酸Test Wako(和光 純藥製造)來測定,結果如第3圖。血漿肌酸濃度則用尿 素氮B-Tes t Wako(和光純藥製造)測定,結果如第4圖。 試驗例2 將從4週齡W i s t a r系雄鼠之腎小球調製之環間膜細胞 在96穴板每穴接種1 000個細胞,在含20%牛胎兒血淸之 RPMI培養基培養24小時。在20小時,44小時後,每穴添 加1 0萬dpm之3H -胸苷,4小時後,將細胞洗淨而以0 . 1 % SDS,0 . lmg/ml脫氧膽酸酯溶解,以液體閃爍計測定放射 活性來測定3H -胸苷吸入量而算出吸入率,結果如第5圖。 從第1圖及表1 2得知,在檢體投與群顯著抑制尿中蛋 白排泄量。已知尿中蛋白排泄量乃在腎小球障害時增加(人 也如此),可爲腎小球機能衰竭之良好指標。尿中蛋白排泄 量在E-30投與後顯著增加,在投與抗體之老鼠呈示腎功能 -66- 1249518 下降。因在檢體投與群顯著地抑制尿中蛋白之排泄,故檢 體化合物作爲腎小球障害之防治劑有效。 由第2圖得知,在檢體投與群抑制細胞增殖。抗體投與 5日後,在腎小球內呈現環間膜細胞之異常增殖(由光學及 電子顯微鏡之觀察)。此增殖中之細胞可由細胞周期之s期 呈現PCNA之免疫組織化學法染色來鑑定。故就無處理群與 檢體投與群比較每個腎小球之陽性細胞數得知上述發現。 從第3圖得知,在檢體投與群顯著地抑制血中尿素N濃 度。可見在檢體投與群抑制腎功能(腎小球過濾功能)下降, 結果得知檢體化合物作爲腎小球障害之防治劑有效。 從第4圖得知,在檢體投與群顯著抑制血漿中肌酸濃度。 可見在檢體投與群抑制腎功能(腎小球過濾功能)下降,結 果得知檢體化合物作爲腎小球障害之防治劑有效。 從第5圖得知,對由血淸刺激之環間膜細胞增殖,隨檢 體濃度而抑制細胞增殖。在此由第2圖確認所得細胞增殖 之抑制作用是否直接作用於環間膜細胞。 由以上之結果得知,本發明之化合物抑制隨伴於腎小球 障害之尿中蛋白排泄量之增加,對具於大半腎小球障害之 環間膜細胞增殖也有抑制作用。所用實驗模式中引起之病 態爲人腎小球腎炎及糖尿病性腎症共通者。故本發明之化 合物可當作腎小球緊炎及糖尿病性腎症之防治劑。 試驗例3 MMP - 9,MMP - 2之抑制活性測定方法 酵素活性之測定仿C . G r a h a m K n i g h t,F r a n c e s -67- 1249518
Wi 1 lenbrock and Gillian Mu r p h y 1 ; A novelcoumarin-labelled peptide for sensitive continuous assays of the matrix metallpproteinases: FEBS Lett.,296、 (1992)、 263-266 〇 MMP-9 ^ Y.Okada et al.(Yasunori Okada,Yukio Gonoji, Katsumi Naka,Katsuro Tomitajsao Nakanishi,Kazushi Iwata.Kyoko Yamashita,and Taro Hayakawa. Matrix metalloproteinase 9(92-kDa gelatinase/type IV collagenase) from HT1080 human fibrosarcoma cells. Purification ancl activation of the precursor and enzymic properties J.Biol.Chem 1992,267,21712-21719)及其他方法(① Yasunori Okada, Tatsuhisa Morodomi, Jan J.Enghild, ko Suzuki, Atsushi Yasui, Isao Nakanishi Guy salvesen and Hideaki Nagase、 Matrix metalloproteinase 2 from human rhumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur.J.biochem. 1990,194,721-730 ② Robin V.Ward, Rosalind MJIembry, John J.Reynolds and Gillian Murphy The purification of tissue inhibitor of metalloproteinase‘2 from its 72kDa progelatinase complex. Biochem.J 1991,278,179-187) 組合單離 及精製。即將人纖維瘤細胞ATCC HT1 080在37°C含10%牛 胎兒血淸(FCS)之Dulbecco修飾培養基(DMEM)培養48小時 (5% )來共融。共融細胞在去除FCS之DMEM再培養(2nd)。 此培養時欲得ΜΜΡ·9,在DMEM中加50ng/ml之Phorbol-12-十四酸-1 3 -乙酸酯(TPA),將TPA處理培養液離心(300 Or pm, 15分),將上淸以超濾(UP-20,東洋濾紙)濃縮,至約450ml, 而在明膠- Sepharose,Concanaralin A-Sepharose 精製。 -68- 1249518 次將MMP-9劃分予以透析,超濾(UP-20,東洋濾紙)來濃縮。 而吸附溶出在Sepharryl S-200,Green A基質來進行與 ΤΙ MP之分離。次將前膠原酶以TPCK-胰蛋白酶(最後濃度3 # g / 5 0 // R e a c t · M i x )活性化來供分析。 MMP-2乃購自野外公司(山形縣山形市富神台8號)。 基質 Μ 0 C A c - P r 〇 - L e u - G 1 y - L e u - A 2 P r ( D n p ) - A 1 a - A r g - N Η 2 乃購自胜肽硏究所(大阪府箕面市)。基質乃以ImM/DM SO溶 液爲保存溶液來調製。 反應所用之緩衝液爲 50mM Tr i s - HC1 (pH7 . 5 ),10mM CaCl2, 0.3M NaCl, 0.005% Brij 35,0.01% NaN3 ° (MMP - 9之抑制試驗)··試驗化合物1 . 0 // 1,頗含有酵素 液0.08// 1之反應緩衝液48.0// 1之混合物49.0// 1在室 溫預備反應6 0分後,加基質1 · 0 // L,在室溫6 0分後,力口 3%乙酸水溶液100/z 1來停止反應,測定Ex3 2 0nm,Em40 5nm 之螢光強度(測定器:Labsystems公司製造,Fluoroskan Ascent)。 (匪P - 2之抑制試驗):試驗化合物1 · 〇 // 1,頗含有酵素 液0.0 5 // 1之反應緩衝液4 8 . 0 # 1之混合物4 9 · 0 β 1在室 溫預備反應6 0分後,加基質1 · 0 /z L,在室溫6 0分後,加 3%乙酸水溶液100// 1來停止反應,測定Ex3 20nm,Em405nm 之營光強度(測定器· Labsystems公司製造,Fluoroskan Ascent)0 抑制強度(IC5。)由如下實驗求出。 -69- 1249518 抑制劑之分析乃就1個化合物(抑制劑)施行如下4種 分析: (A)基質(合成基質),酵素(MMP-9或MMP-2),抑制劑 (B )基質(合成基質),抑制劑 (C) 基質(合成基質),酵素(MMP-9或MMP-2) (D) 基質(合成基質) 就各(A)(D)測定營光強度’依下式求出抑制(%) 抑制(%)= {1-(Α-Β)/((Μ))} χι〇〇 I C5。爲抑制(% )成50%之濃度,林s ^ w果如表1 3。
•70- 1249518 表1 3 化合物 No. IC50 (ΜΜΡ·2) (μΜ) IC5〇 (ΜΜΡ-9) (μΜ) 87 0.003687 0.01 95 0.0107 0.019 96 0.0015 ϋ.0302 97 0.01557 0.1360 98 0.0953 0.787 99 0.00459 0.04926 103 0.00612 0.0278 104 0.00202 0.01867 105 0.04137 0.3042 106 0.02827 0.1037 107 0.00351 0.00825 108 0.00992 0.0312 109 0.00471 0.0132 110 0.0257 0.0947 111 0.01069 0.1042 112 0.02842 0.1263 113 0.005701 0.07179 114 0.02778 0.3161 115 0.181 4.61 116 0.01224 0.09401 117 0.002619 0.03098 118 0.002159 0.06161 119· 0.001693 0.04549 120 0.0009195 0.005815 121 0.000561 0.148 -71- 1249518 製劑例1 製造含下列成份之顆粒劑 成分 化合物(I) 10mg 乳糖 700mg 玉米彳殿粉 274mg HPC-L 16mg 10 0 Omg 將化合物(I )及乳糖篩經60篩孔,玉米澱粉篩經1 20篩 肇 孔。兩者在V型混合機混合而加HPC-L(低粘度羥丙基纖維 素)水溶液,予以捏合及造粒(擠壓造粒,孔徑0.5〜lmm)及 乾燥。所得乾燥顆粒篩經振動篩(1 2/ 60篩孔),得顆粒劑。 製劑例2 製造含下列成份之膠囊充塡用散劑: 成分 化合物(I ) 、:I Omg 乳糖 7 9 m g 玉米激粉 10mg 硬脂酸鎂 1 m g 1 OOmg 將化合物(I )及乳糖篩經60篩孔,玉米澱粉篩經120篩 孔。這些與硬脂酸鎂在V型混合機混合。所得10倍數100mg 充塡在5號硬膠囊。 -72- 1249518 製劑例3 製造含下列成份之膠囊充塡用顆粒劑: 成分 化合物(I ) 1 5mg 乳糖 90mg 玉米澱粉 42mg HPC-L 3mg 1 5 Omg 將化合物(I )及乳糖篩經 60篩孔,玉米澱粉篩經120篩 孔。將這些混合而加HPC - L溶液,予以捏合,造粒及乾燥 所得乾燥顆粒予以整粒後, 其150mg充塡在4號硬膠囊。 製劑例4 1 製造含下列成份之錠劑 ·· 成分 化合物(I ) 1 Omg 乳糖 90mg 微晶纖維素 30mg MC-Na 1 5mg 硬脂酸鎂 5mg -73- 1 5 Omg 將化合物(I ),乳糖,微晶纖維素,CMC - N a (羧甲基纖維 素鈉鹽)篩經60篩孔而混合後,混合硬脂酸鎂,得製錠用 混合末。將此直接打錠,得1 5〇mg錠劑。
Claims (1)
- I2495i8 I、申請專利範圍:、一第—9r 4〇5 號腎小球障害防治劑」專利案 (2005年5月5曰修正) 1_ 一種腎小球障害防治劑,內含有效成分爲如下式(D化合 物,其光學活性體,或其製藥容許鹽: R1 R4-R3-S02-N 入 COY (I) R2〔式中 R1爲Η、可經苯胺甲醯基或(^_6烷硫基取代之直鏈或 分支鏈1.6烷基、可經羥基取代之苯基、苯基烷 基,或可經(^.4烷氧基取代之吲哚基甲基; R2爲Η或CV6烷基; 尺3爲1,4_伸苯基或2,5-噻吩二基; R4爲(式中R5爲Η、羥基、可經1或2個烷基取代之胺 基所取代之(^.6烷氧基、CV6烷硫基、鹵素、羧基、cv6 烷氧羰基、硝基、氰基、CV6鹵烷基、可經1或2個(V6 1249518 烷基取代之胺基、可經疊氮基或羥基取代之cU6院基、c 1-6 醯基、醯氧基、-CONRARB(RA及RB爲相同或相異,各爲H、 或C!.6烷基)、-NHCORD(式中RD爲C〗·6烷基),或嗎啉基; R6爲可經羥基取代之C!.6烷基、C!·6烷氧基、Cl6烷硫基、 可經1或2個C6烷基取代之胺基、苯基、嗎啉基,或 吡咯啶基); Y 爲 NHOH 或 0H〕。 2 ·如申請專利範圍第1項之腎小球障害防治劑,其中一般式 (I )之R4爲:(式中R5爲Η、經基、Ci.6院氧基、1_6院硫基、鹵素、 羧基、1_6烷氧羰基、硝基、氰基、鹵烷基、可經疊 氮基或羥基取代之Ci.6烷基,或6烷醯基; R6爲可經羥基取代之Cl6烷基,或苯基)。 3 ·如申請專利範圍第1項之腎小球障害防治劑,其中一般 式(I)之R4爲·1249518 (式中R5爲Η、可經1或2個烷基取代之胺基所取代 之Cm烷氧基、CV6烷硫基、鹵素、可經1或2個Cm烷 基取代之胺基、可經疊氮基或羥基取代之C!.6烷基’或 嗎啉基; R6爲可經羥基取代之Cu烷基、Cu烷硫基、可經1或2 個Cle6烷基取代之胺基、苯基、嗎啉基,或吡咯啶基)。 4 .如申請專利範圍第1項之腎小球障害防治劑,其中一般式 (I )之R4爲:IR6,(式中R5爲Η、鹵素、可經疊氮基或羥基取代之1_6烷基’ CV6烷氧基,或CV6烷硫基; R6爲可經羥基取代之<^.6烷基或苯基)。 5 .如申請專利範圍第1項之腎小球障害防治劑,其一般式(I ) 爲如下式(I 11 )化合物:(式中R1,R2及Y同申請專利範圍第1項之定義,R1()爲 同申請專利範圍第3項之R5之定義 )。 6 ·如申請專利範圍第1項之腎小球障害防治劑,其一般式(I ) 爲如下式(I V )化合物: 1249518 R11 人 COY (IV) R2 (式中R1、R2及Y同申請專利範圍第1項之定義,Ri2與 申請專利範圍第4項之R5同意義)。 7 .如申請專利範圍第1項之腎小球障害防治劑,其一般式(I ) 爲如下式(V )化合物=(式中R1、R2及Y同申請專利範圍第1項之定義,R1Q同 申請專利範圍第3項之R5之定義)° 8 .如申請專利範圍第1項之腎小球障害防治劑’其一般式(1 ) 爲如下式(V I )化合物:(VI)(式中R1、R2及Y同申請專利範圍第1項之定義,Rl2與 申請專利範圍第4項之r5同意義)° 9 .如申請專利範圍第1項之腎小球障害防治劑,其一般式(1 ) 爲如下式(V I I )化合物: R1 (VII) 六 COY (式中Ri'R2及γ同申請專利範圍第1項之疋義,R同 -4- 1249518 申請專利範圍第3項之R5之定義)。 1 0 ·如申請專利範圍第1項之腎小球障害防治劑,其一般式 (I )爲如下式(V I I I )化合物:(VIII) (式中R1,!?2及Y同申請專利範圍第1項之定義,R12與 申請專利範圍第4項之R5同意義)。 1 1 ·如申請專利範圍第1項腎小球障害防治劑,其一般式(I ) 爲如下式(XI)化合物,其光學活性體,或其製藥容許鹽: — R1 卜c〇y (χι) (式中R1,R2及Y同申請專利範圍第1項之定義,R1Q與 申請專利範圍第3項之R5同意義)。 1 2 ·如申請專利範圍第1項之腎小球障害防治劑,其一般式 (I)爲如下式(XII)化合物: R1 (ΧΠ) S02—N 人COY R2 (式中R1,R2及Y同申請專利範圍第1項之定義’ R12與 申請專利範圔第4項之R5同意義)。 i 3 .如申請專利範圍第1項之腎小球障害防治劑,其一般式 (I)爲如下式(XIII)化合物: (XIII) 1249518(式中R1、R2及γ同申請專利範圍第1項之定義,R1()與 申請專利範圍第3項之R5同意義)° 14•如申請專利範圍第1項之腎小球障害防治劑,其一般式 (I)爲如下式(XIV)化合物: R1 SO2-N^COY (XIV) R2 (式中R1、R2及Y同申請專利範圍第1項之定義’ Rl2與 申請專利範圍第4項之R5同思義)。 1 5 ·如申請專利範圍第1項之腎小球障害防治劑,其一般式R1 so2-n^coy (XV) * R2 (式中Ri'R2及Y同申請專利範圍第1項之定義’Rl1同 申請專利範圍第3項之R6定義)。 1 6 .如申請專利範圍第1項之腎小球障害防治劑,其一般式 (I )爲如下式(XVI )化合物: (I)爲如下式(XV)化合物:R1 -N 入 COY (XVI) R2 (式中R1、R2及Y同申請專利範圍第1項之定義’ Rl3同 申請專利範圍第4項之R6定義)。 -6-1249518 1 7 ·如申請專利範圍第1〜1 6項中任一項之腎小球障害防治 劑,其中R1爲H、甲基、異丙基、異丁基、苄基、可經Ci 6 烷氧基取代之(吲哚-3 -基)甲基,或苯胺羰乙基。 1 8 ·如申請專利範圍第1〜1 6項中任一項之腎小球障害防治 劑’其中R1爲異丙基,;基,或(卩弓丨哚-3-基)甲基。 1 9 ·如申請專利範圍第1〜1 6項中任一項之腎小球障害防治 劑,其中R2爲Η。 20 ·如申請專利範圍第1〜1 6項中任一項之腎小球障害防治 劑,其中γ爲ΟΗ。 _ 21 ·如申請專利範圍第1〜1 6項中任一項之腎小球障害防治 劑,其中腎小球障害爲腎小球腎炎。 22 ·如申請專利範圍第1〜1 6項中任一項之腎小球障害防治 劑’其中腎小球障害爲糖尿病性腎症。 2 3 ·如申請專利範圍第1項之腎小球障害防治劑,其中一般 式(I)爲如下式(XX IV)化合物: • R1 Τ (XXIV) R15 - S02-N COY R2 * (式中各取代基之組合如下): 1249518 化合物 Να Υ R1 R2 Rl« 1 ΝΗΟΗ (ΟΗ3)2〇Η- H 2 ΝΗΟΗ (ch3)2ch- Me 3 ΟΗ H 4 ΝΗΟΗ 〇ϊ陶- ·. H 5 ΟΗ (CEb)2GH. H o-o^- 6 ΟΗ PhCH2- H QrQrQr 7 ΟΗ (CH3)2CH- H Me0HQj[^L 8 ΟΗ H MeS-H〇JTjL 9 ΝΗΟΗ (CH3)銀, H MeS^^TjL 10 ΟΗ (CH3)2CH· H Β〇^0_ις]]_ 11 ΟΗ (CH3)2CH: H 12 ΟΗ PhCH2- H Me2NH^^—Cpi— 13 ΟΗ (CH3)2CH.· H 14 ΟΗ H 15 ΟΗ (CH3)2CH· H E 丨 16 ΟΗ. (CH3)2CH- H El 17 ΟΗ PhCHs- . · * H Me ,. ,-, Et 18 ΟΗ PhCH!- .H B2NHQJ[^ 1249518 化合物 NO. 1 Y Rl R2 R15 19 OH ch3- H .Me2N-^yJlsl— 20 OH PhCH2· H 21 OH PhCHi- H MeHN"~^ — 22 OH CH3· H · Me2N-QjriL 23 OH PhCH2- a 24 OH CHV H , Et 25 OH (CH3)2CH‘ H H2NHQJ[^L 26 OH (CH3)2〇H- H H0H2C-^JH< gi— 27 . OH (CH 咖 CH- H 28 OH H H 29 .OH H t H 30 OH iX^iCH2) H 31 OH (CH3)2CH· · H 32 OH phcm- H 33 NHOH PhCH2- H 34 OH PhCH2T H 35 OH H 36 OH H 〇 37 OH H 1249518 化合物 NO. Y R1. R2 R15 38 OH (CH3)2CH- H 39 OH (CH3)2CH. H ο- 40 OH 〇ώ-,〇Η,- H 41 OH PhCH2- H 42 - NHOH (CH3)2CH- H Μβ〇Η0^· 43 OH PhCHa- H Η〇νΆ〇^·Ν^~0~ 44 OH PhCHz- r .· H 45 OH (CH3)2CH· H 46 OH (CHACH: H 47 OH (CH3)2CH- · H 48 OH PhNHOO(CH2)2- H Meo-O-C^- 49 OH PhCHz- H 50 OH PhCHV H 51 OH (CH3)2CH- H 52 OH· (ch3)2chch2· H 53 OH (CH3)2CH. H 54 OH (ch3)2ce· H 一㊈:办 55 OH (ch3)2ch H h2nochQ^.n^h^^--10- 1249518 化合物 NO. Y Ri R2 R15 56 OH (CH3)2CH- H 57 OH CHa- H F-h0KN,n^LhQ- 58 OH (GH3)2CH- H 59 OH MeS-CH2CH2- H 60 OH 4-OH-Ph· H 61 OH PhCHa- H 62 OH PhCH2- •H 63 OH (CH3)2CH·. H C=C"AS J~ 64 OH (CH1O2CH- H 65 NHOH (CH3)2CH- H Me_Q_cscJgL 66 OH PhCH2- ϋ Cl- 67 OH PhCHi, H · 68 OH H 69 OH 〇ώ-,〇Η,- H Me〇H^^C=C-X^jL 70 NHOH 〇ώ-,〇Η,- H 71 NHOH (CHs)2CH- H MeSH〇HCScJ^]l— 72 NHOH H Cl— 73 OH H Cl—-11- 1249518 化合物 N〇. Y Ri R2 74 OH (CH3)2CH- H ci— 75 OH (CHs)2CH. H Et-三 cJLsji— 76 OH 〇&L_- H Ht— 77 OH PiiCHs. H MeS-^^CScAgJ— 78 OH H MeS-^^-CEC 成 SJL 79 OH (ch3)2ch· H m©s--^^chcAsJ—· 80 NHOH H Q|—. 81 OH H 82 OH 〇i_- H 83 OH 〇^-(〇h,- H h〇s/^Q^c4^]L 84 OH (CHs)2CH- H 85 OH PhCHa- H ho-^q-cscJ[^l 86 OH 〇Al_ H 87 OH PI1CH2- H Me^gicsc^gJ— 88 OH 0^_- H Me^3"csc^^~ 89 NHOH H 95 OH PhCH2- H 96 OH (CH3)2CH. H MeHQ^:JU^L 97 OH (CH3)2CH. H-12- 1249518 化合物 NO. Y Ri R2 100 OH (CHs)2CH- H 101 OH (CHs)2CH- H 102 OH (CH8)2CH- H >〇r<y 104 OH <CH3)2CH- H 105 OH PhCHs- H 106 OH (CHs)5CH- H 107 OH (CHs)2CH. H 108 OH PhCHs- H 分 109 OH H 110 OH PliCHs* H 111 OH ㈣一 H 112 OH (CH3)2CH- H 113 OH (CH3)sCHCH^ H b"〇U^nj;iHQ~ 114 OH CHh H 分 115 OH PhCH2- H 抑分 116 OH H H 曰分-13- 1249518 化合物 NO. Y Ri R2 Ru 117. OH CHs- H 118 OH (CH3)2CH- H 119 OH (ch3)2ch- H 120 OH (ch3)2ch· H 121 OH (CHs)2CH- H 24 .如申請專利範圍第1項之腎小球障害防治劑,其一般式 (I )爲如下式(XXIV)化合物: R1 R15-S02-N^C0Y (XXIV) R2 (式中各取代基之組合如下):-14- 1249518 表2 化合物 No. Y R2 1 ΝΗΟΗ (CH3)2CH- H 2 ΝΗΟΗ (CH3)2CH- Me 3 OH H O^0hQ- 4 ΝΗΟΗ H 〇-°-〇- 5 OH (CH3)2CH- H 6 OH PI1CH2- H Q-Q-O- 7 OH (GHs)2CH. H MeO^^JTjL 31 OH (ch3)2ch· H 32 OH PhCH^ H O-K^O- 33 NHOH PlxCHs- H O-K^-O- 34 OH PhCHa- H 35 OH H Me〇-〇-K^〇- 36 OH H 37 OH H 38 OH (CHs)2CH- H -O-K^O- 39 OH (ch3)2ch- H 63 OH (ch3)2ch- H MeO-^^-CrC-iLgJJ—- 64 OH (CH3)2CH- H-15- 1249518 化合物 No. Y Ri R2 65 NHOH (CHs)2CH- H Me-^^C=C^SJL 66 OH PhCH2- H Cl—^^-CEC-lgjL- 67 OH PhCH2- H 68 OH 〇ώ-(〇Η,- H 69 OH H C=C-AgJJ— 70 NHOH H Me,~^3~C5C^S^— 71 NHOH (CH3)2CH· H MeS-^^CSC^gjL 72 NHOH H ci-^^c=c4^jL 88 OH H M eC S C 89 NHOH H 25 26 .如申請專利範圍第23或24項之防治劑,其中腎小球障 害爲腎小球腎炎。 .如申請專利範圍第2 3或24項之防治劑,其中腎小球障 害爲糖尿病性腎症。 -16-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP19541497 | 1997-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200400934A TW200400934A (en) | 2004-01-16 |
TWI249518B true TWI249518B (en) | 2006-02-21 |
Family
ID=16340702
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092118405A TWI249518B (en) | 1997-07-22 | 1998-09-30 | An agent for treating or preventing a rennal glomeralus disfunction |
TW087111798A TW593249B (en) | 1997-07-22 | 1998-09-30 | An agent for treating or preventing a renal glomerulus dysfunction |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW087111798A TW593249B (en) | 1997-07-22 | 1998-09-30 | An agent for treating or preventing a renal glomerulus dysfunction |
Country Status (21)
Country | Link |
---|---|
US (2) | US6423729B1 (zh) |
EP (2) | EP1029541B1 (zh) |
JP (1) | JP3621427B2 (zh) |
KR (1) | KR100386148B1 (zh) |
CN (1) | CN1198607C (zh) |
AT (1) | ATE320801T1 (zh) |
AU (1) | AU737218B2 (zh) |
BR (1) | BR9811521A (zh) |
CA (1) | CA2297011C (zh) |
DE (2) | DE69833940T2 (zh) |
HU (1) | HUP0003851A3 (zh) |
ID (2) | ID24105A (zh) |
IL (1) | IL133933A0 (zh) |
NO (1) | NO20000285L (zh) |
NZ (1) | NZ502274A (zh) |
PL (1) | PL338235A1 (zh) |
RU (1) | RU2207849C2 (zh) |
SK (1) | SK262000A3 (zh) |
TR (2) | TR200000214T2 (zh) |
TW (2) | TWI249518B (zh) |
WO (1) | WO1999004780A1 (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1198607C (zh) * | 1997-07-22 | 2005-04-27 | 盐野义制药株式会社 | 治疗或预防肾小球病的组合物 |
CA2318145C (en) | 1998-02-04 | 2009-10-27 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
WO2000015213A1 (fr) * | 1998-09-11 | 2000-03-23 | Shionogi & Co., Ltd. | Agent de prevention ou de traitement de l'insuffisance cardiaque congestive |
WO2000063194A1 (fr) * | 1999-04-19 | 2000-10-26 | Shionogi & Co., Ltd. | Derives de sulfonamide possedant des noyaux oxadiazole |
FR2798589B1 (fr) * | 1999-09-16 | 2001-11-30 | Oreal | Composition cosmetique comprenant au moins un copolymere silicone/acrylate et au moins un agent epaississant |
EP1270569A4 (en) * | 2000-01-26 | 2005-01-05 | Shionogi & Co | SUBSTITUTED TRYPTOPHAN DERIVATIVES |
WO2001070675A2 (en) * | 2000-03-24 | 2001-09-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2001083464A1 (fr) * | 2000-04-21 | 2001-11-08 | Shionogi & Co., Ltd. | Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire |
MXPA02010325A (es) * | 2000-04-21 | 2003-04-25 | Shionogi & Co | Derivados de oxadiazol los cuales tienen efectos anticancer. |
WO2001083461A1 (fr) * | 2000-04-28 | 2001-11-08 | Shionogi & Co., Ltd. | Derives de thiazole et d'oxazole |
WO2001083431A1 (fr) | 2000-04-28 | 2001-11-08 | Shionogi & Co., Ltd. | Inhibiteurs de mmp-12 |
WO2002028844A1 (fr) * | 2000-09-29 | 2002-04-11 | Shionogi & Co., Ltd. | Dérivés thiazole ou oxazole |
WO2003031419A1 (en) | 2001-10-09 | 2003-04-17 | 3-Dimensional Pharmaceuticals, Inc. | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes |
ES2331177T3 (es) * | 2001-12-14 | 2009-12-23 | Exelixis, Inc. | Inhibidores de adam-10 humana. |
DK1511472T3 (da) | 2002-05-29 | 2009-08-24 | Merck & Co Inc | Anvendelige forbindelser til behandling af Anthrax og hæmning af letalfaktor |
WO2005012268A1 (ja) | 2003-07-30 | 2005-02-10 | Shionogi & Co., Ltd. | イソオキサゾール環を有するスルホンアミド誘導体 |
US7504431B2 (en) * | 2004-04-16 | 2009-03-17 | Bristol-Myers Squibb Company | Sulfonyl amide inhibitors of calcium channel function |
AU2005250351A1 (en) | 2004-05-11 | 2005-12-15 | Merck & Co., Inc. | Process for making n-sulfonated-amino acid derivatives |
JP2006036691A (ja) * | 2004-07-27 | 2006-02-09 | Shionogi & Co Ltd | 腎炎の治療または予防剤 |
US20080119513A1 (en) * | 2004-09-06 | 2008-05-22 | Fumihiko Watanabe | Sulfonamide Derivative Selectively Inhibiting Mmp-13 |
US7576222B2 (en) * | 2004-12-28 | 2009-08-18 | Wyeth | Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase |
US20090069304A1 (en) | 2006-03-03 | 2009-03-12 | Shionogi & Co., Ltd. | Mmp-13 selective inhibitor |
EP2128134A1 (en) | 2006-11-02 | 2009-12-02 | Shionogi&Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
RU2528333C2 (ru) * | 2008-12-23 | 2014-09-10 | Аквилус Фармасьютикалз, Инк | Соединения и способы лечения боли и других заболеваний |
AU2018317812C1 (en) | 2017-08-17 | 2021-08-26 | Glaxosmithkline Intellectual Property Development Limited | Novel tetrazole compounds and their use in the treatment of tuberculosis |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506242A (en) | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
JP3818322B2 (ja) * | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
GB2303629B (en) | 1994-06-22 | 1998-09-02 | British Biotech Pharm | Hydroxamic acids and their use as metalloproteinase inhibitors |
KR980009238A (ko) * | 1995-07-28 | 1998-04-30 | 우에노 도시오 | 설포닐아미노산 유도체 |
ATE226936T1 (de) | 1995-08-08 | 2002-11-15 | Ono Pharmaceutical Co | Hydroxamsäurederivate verwendbar zur hemmung von gelatinase |
KR19990036271A (ko) | 1995-08-08 | 1999-05-25 | 토마스 네프 | 콜라겐 과다생산과 연관된 질환의 치료에 이용되는 c-프로테나제 저해물질 |
JPH09110864A (ja) | 1995-08-10 | 1997-04-28 | Kureha Chem Ind Co Ltd | クロモン誘導体、その製造方法及び医薬組成物 |
JPH0987178A (ja) | 1995-09-22 | 1997-03-31 | Toyama Chem Co Ltd | 神経成長因子の作用増強剤 |
JPH0987176A (ja) | 1995-09-26 | 1997-03-31 | Shiseido Co Ltd | 糸球体腎炎抑制剤 |
JP3628335B2 (ja) | 1996-01-23 | 2005-03-09 | 塩野義製薬株式会社 | スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤 |
CA2242416C (en) * | 1996-01-23 | 2006-03-21 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
PT901466E (pt) * | 1996-05-17 | 2002-04-29 | Warner Lambert Co | Bifenilsulfonamidas como inibidores de metaloproteinases da matriz |
WO1997045402A1 (fr) | 1996-05-24 | 1997-12-04 | Ono Pharmaceutical Co., Ltd. | Derives de phenylsulfonamide |
JP2000515153A (ja) | 1996-07-22 | 2000-11-14 | モンサント カンパニー | チオールスルホンアミド メタロプロテアーゼインヒビター |
EP0973748A1 (en) * | 1997-04-01 | 2000-01-26 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
CN1198607C (zh) * | 1997-07-22 | 2005-04-27 | 盐野义制药株式会社 | 治疗或预防肾小球病的组合物 |
-
1998
- 1998-07-17 CN CNB98809147XA patent/CN1198607C/zh not_active Expired - Fee Related
- 1998-07-17 AU AU82439/98A patent/AU737218B2/en not_active Ceased
- 1998-07-17 IL IL13393398A patent/IL133933A0/xx unknown
- 1998-07-17 DE DE69833940T patent/DE69833940T2/de not_active Expired - Lifetime
- 1998-07-17 RU RU2000103032/04A patent/RU2207849C2/ru not_active IP Right Cessation
- 1998-07-17 CA CA002297011A patent/CA2297011C/en not_active Expired - Fee Related
- 1998-07-17 US US09/462,001 patent/US6423729B1/en not_active Expired - Fee Related
- 1998-07-17 NZ NZ502274A patent/NZ502274A/xx unknown
- 1998-07-17 SK SK26-2000A patent/SK262000A3/sk unknown
- 1998-07-17 ID IDW20000054A patent/ID24105A/id unknown
- 1998-07-17 HU HU0003851A patent/HUP0003851A3/hu unknown
- 1998-07-17 AT AT98932574T patent/ATE320801T1/de not_active IP Right Cessation
- 1998-07-17 PL PL98338235A patent/PL338235A1/xx unknown
- 1998-07-17 EP EP98932574A patent/EP1029541B1/en not_active Expired - Lifetime
- 1998-07-17 TR TR2000/00214T patent/TR200000214T2/xx unknown
- 1998-07-17 KR KR10-2000-7000676A patent/KR100386148B1/ko not_active IP Right Cessation
- 1998-07-17 TR TR2001/00389T patent/TR200100389T2/xx unknown
- 1998-07-17 BR BR9811521-9A patent/BR9811521A/pt not_active Application Discontinuation
- 1998-07-17 EP EP03023547A patent/EP1398027B1/en not_active Expired - Lifetime
- 1998-07-17 WO PCT/JP1998/003226 patent/WO1999004780A1/ja active IP Right Grant
- 1998-07-17 JP JP50964999A patent/JP3621427B2/ja not_active Expired - Fee Related
- 1998-07-17 DE DE69836877T patent/DE69836877D1/de not_active Expired - Lifetime
- 1998-07-17 ID IDW00200101551A patent/ID29293A/id unknown
- 1998-09-30 TW TW092118405A patent/TWI249518B/zh not_active IP Right Cessation
- 1998-09-30 TW TW087111798A patent/TW593249B/zh not_active IP Right Cessation
-
2000
- 2000-01-20 NO NO20000285A patent/NO20000285L/no not_active Application Discontinuation
-
2002
- 2002-06-06 US US10/162,865 patent/US6878739B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI249518B (en) | An agent for treating or preventing a rennal glomeralus disfunction | |
US7534897B2 (en) | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism | |
KR101284573B1 (ko) | 신규한 트리시클릭 안지오텐신 ⅱ 아고니스트 | |
JP5408434B2 (ja) | アミド化合物 | |
TWI244474B (en) | A sulfonated amine acid derivative and the metalloproteinase inhibitor containing it | |
TW201311658A (zh) | 有益於治療關節炎之新穎咪唑衍生物 | |
TW201105658A (en) | Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators | |
Park et al. | Investigations of new lead structures for the design of novel cyclooxygenase-2 inhibitors | |
EP3704112A1 (en) | Alkene spirocyclic compounds as farnesoid x receptor modulators | |
JPH06500997A (ja) | 抗炎症/抗アレルギー剤用ナフタレンプロピオン酸誘導体 | |
TW200523249A (en) | Novel heteroaryl derivative | |
KR20080011282A (ko) | 신규한 비시클릭 안지오텐신 ⅱ 아고니스트 | |
JP4707321B2 (ja) | アンギオテンシンiiアゴニストとして有用な三環式化合物 | |
US6156784A (en) | Compounds useful as phosphotyrosine mimics | |
WO2023142214A1 (zh) | 3-羟基-5-(异噁唑-5-基)吡啶甲酰甘氨酸类化合物、制法、药物组合物和应用 | |
WO2021098671A1 (zh) | 含脲基苯并咪唑类衍生物及其制备方法和应用 | |
US11498903B2 (en) | 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases | |
CZ479399A3 (cs) | Prostředky pro léčbu a nebo prevenci glomerulopatie | |
WO2023114819A1 (en) | Tetraline, phenylcyclobutane, and phenylcyclopentane analogs as rxfp1 agonists | |
JP2022519769A (ja) | ファルネソイドx受容体モジュレータとして有用な置換アミド化合物 | |
TW201116522A (en) | 1-(6 members azo-heterocyclic)-pyrrolin-2-one compounds as inhibitors of Hepatitis C NS5B polymerase, the pharmaceutical composition thereof and their therapeutic use | |
CA2363689A1 (en) | Compounds useful as phosphotyrosine mimics | |
MXPA00000712A (en) | Therapeutic or prophylactic agent for glomerulopathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |